Conjoint Professor Peter Wark

Conjoint Professor Peter Wark

Conjoint Professor

School of Medicine and Public Health (Immunology and Microbiology)

Career Summary

Biography

Peter Wark is a senior staff specialist in Respiratory and Sleep Medicine at John Hunter Hospital, Newcastle and a conjoint Professor with the University of Newcastle. In addition he is a senior member of the Priority Research Centre for Healthy Lungs and a member of the Vaccines Immunology Viruses and Asthma research group at the Hunter Medical Research Institute. He has been a member of the TSANZ executive board since and chairman of the clinical care and resources subcommittee since 2011.

His research interests are in the area of infection and the impact this has on inflammatory airways disease, with a particular interest in viral respiratory infections. His group has developed expertise in identifying respiratory viruses in airway secretions and developing an in-vitro cell culture model of the airway epithelium that we use to model the effect of infection and inflammation. He is the centre director for the John Hunter Adult Cystic Fibrosis clinic that manages 75 adult patients with CF in the context of a multidisciplinary team. He is area director for the oxygen and related products scheme and lead physician for the advanced respiratory failure clinic. He is chairperson for the Hunter New England Local Hospital network respiratory stream, responsible for the provision of respiratory services throughout the Hunter New England area, with a catchment population of 840,000.

Peter qualified as a Bachelor of Medicine at the University of Newcastle, Australia in 1991 and qualified as a specialist in Respiratory and Sleep Medicine as a Fellow of the Royal Australasian College of Physicians in 1999. From 2001-2005 he was a post doctoral research fellow under an NHMRC Neil Hamilton Fairley Travelling Fellowship at the University of Southampton and University College London, under the supervision of Professors Stephen Holgate, Donna Davies and Sebastian Johnston. From 1998-2001 he completed a PhD under the supervision of Professors Peter Gibson and Michael Hensley at the University of Newcastle, Australia. Peter is married to Katrina, and parents to Kirsty, Marden, Jasmine, Sarah, David, Charlotte and Eliza.

Research Expertise
My current research interests include the role of virus infection in acute exacerbations of airways disease and their influence on airway inflammation. Active research programmes include the investigation of innate immune function of the airway epithelium in response to virus infection and the interaction with other components of the cellular immune system. These projects involve the use of invitro cell culture models to study mechanisms of disease and inflammation especially in respect to viral and bacterial infection, the isolation, sequencing and characterisation of respiratory viruses from clinical specimens. Clinical studies currently focus on the effect of infection in acute exacerbations of asthma, COPD and cystic fibrosis lung disease. I undertook a post-doctoral research project that is collaboration between Professor Stephen Holgate and Professor Sebastian Johnston. The project is titled “Mechanisms of bronchial epithelial cell activation in response to rhinovirus infection in asthma COPD and normal airways. The aim is to characterise the response and interaction of cultured human bronchial epithelial and mesenchymal cells to experimental rhinovirus infection. The aim is to contrast and compare the inflammatory and reparative response in cells from subjects with varying severities of asthma, COPD and normal controls. During this time I have established expertise with in-vitro culture of tissue cell lines and primary bronchial epithelial cells. In collaboration with Professor Sebastian Johnston I have also established techniques that have enabled me to culture Rhinovirus and infect epithelial cells. We assessed the cytotoxic effect of infection on epithelial cells and determined the mechanisms of cell death using flow cytometry and Annexin binding. In addition the inflammatory response between asthmatic epithelial cells and healthy controls was compared in terms of release of pro-inflammatory mediators, type I interferons and factors that may influence myofibroblast proliferation, by measuring mRNA production using quantifiable PCR in conjunction with protein expression as measured by ELISA. This data has presented at international meetings and is awaiting publication. In the last eighteen months we have received further funding from the UK National Asthma Campaign and the British Medical Association to extend this work examining the effect of infection on an epithelial-mesenchymal co-culture model to determine if there is a relationship between infection and airway wall remodelling and are exploring in greater detail early epithelial intracellular signalling events following infection, particularly in reference to oxidative pathways and interferon ?/? signalling. My research group specialises in: 1. Primary airway epithelial cell culture, especially in regard to responses to infection and inflammation. 2. Basic mechanisms of innate immune responses pathways, with an emphaisis on epithelial cell responses, dendritic cell responses and innate lymphoid responses. 3. Innate and adaptive immune responses to respiratory virus infection, with a special interest in influenza and rhinovirus

Teaching Expertise
Supervison of honours and PhD students in the areas airway inflammation, infection and respiratory disease. I am responsible for funding and supervising 2.0 FTE research assistants and 2.0 FTE post-doctoral research fellows. I have supervised two students who have completed and been awarded their PhD, 2 further students who have completed their doctoral studies and will submit their thesis in 2012 and 3 students that completed their honours year. I am currently the primary supervisor for two PhD students and a secondary supervisor for another three. For the School of Medicine and Public Health, Faculty of Health, University of Newcastle I have regular lecture commitments to years 2, 3, 4 and 5. In addition I act as a clinical tutor for students in year 3, 4 and 5. My direct University teaching commitments are 2.5 hours per week. Supervision of post graduate students: I currently supervise 3 students enrolled in PhDs and one student enrolled in a masters degree with the Faculty of Health, University of Newcastle. I have supervised the following students that have completed and been awarded PhD with the University of Newcastle. 1. Dr Rebecca Forbes awarded 2012 2. Dr Alan Hsu, awarded 2011 2. Dr Shen Yun Adeline Foo, awarded 2011 3. Dr Ahmed Saedsomaelia, awarded 2009 I have supervised the following students that have completed and been awarded honours with the University of Newcastle. 1. Ms Su Ling Loo, First class Honours awarded 2010. 2. Ms Hayley See,


Collaborations
Our clinical studies currently focus on the effect of infection in acute exacerbations of asthma, COPD and cystic fibrosis lung disease. Ongoing clinical research programmes are active with Prof Peter Gibson, Dr L Wood. We are currently taking part in a multi-centre RCt of non-CF bronchiectasis in collaboration with Royal Prince Alfred Hospital Sydney and Prince Charles Hospital Brisbane. We are an active site involved in the national influenza surveillance programme "Flucan". This works involves an effective collaboration between other members of the VIVA group and priority research centre in the areas of clinical research and translational research using animal models with Prof P Hansbro, Prof J Mattes, Prof P Forster. We have an active NHMRC grant looking at the immunology and susceptibility of virus infection in pregnancy with Prof R Smith.


Qualifications

  • PhD, University of Newcastle
  • Bachelor of Medicine, University of New South Wales

Keywords

  • Airway inflammation
  • Asthma
  • COPD
  • Immunolgy
  • Internal medicine
  • Respiratory Medicine
  • Sleep medicine
  • Virology

Fields of Research

Code Description Percentage
110799 Immunology not elsewhere classified 25
110203 Respiratory Diseases 50
110804 Medical Virology 25

Professional Experience

Academic appointment

Dates Title Organisation / Department
1/01/2010 -  Editor - Clinical and Experimental Allergy Clinical and Experimental Allergy
Australia
1/01/2005 -  Conjoint Associate Professor University of Newcastle
School of Medicine and Public Health
Australia
1/01/2003 -  Fellow - American Thoracic Society American Thoracic Society
United States
1/01/2000 -  Editor - Cochrane Collaboration Cochrane Collaboration
United Kingdom
1/01/1996 -  Fellow - Thoracic Society of Australia and New Zealand The Thoracic Society of Australia and New Zealand
Australia
Edit

Publications

For publications that are currently unpublished or in-press, details are shown in italics.


Chapter (7 outputs)

Year Citation Altmetrics Link
2014 Hsu A, Zhong H, Hansbro P, Wark P, 'Innate Immunity in the Airways to Respiratory Viruses', Virology II - Advanced Issues, iConcept Press, Hong Kong 1-32 (2014) [B1]
Co-authors Alan Hsu, Philip Hansbro
2014 Hsu A, Loo S, Fathi Aghdam F, Parsons K, Hansbro P, Wark P, 'Airway Epithelial and Early Innate Immune Responses to Virus Infections', Human Respiratory Viral Infections, CRC Press, Boca Raton, FL 29-44 (2014) [B1]
DOI 10.1201/b16778-5
Co-authors Philip Hansbro, Alan Hsu
2011 Wark PA, Hayes M, 'Respiratory examination', Clinical Examination: A Problem Based Approach, World Scientific Publishing, Singapore 17-40 (2011) [B2]
2010 Wark PA, Gibson PG, 'Pathogenesis of ABPA', Aspergillosis: From diagnosis to prevention, Springer, Berlin 695-706 (2010) [B1]
Co-authors Peter Gibson
2007 Wark PAB, 'Difficult Asthma', Evidence-based Respiratory Medicine 205-216 (2007)
DOI 10.1002/9780470987377.ch16
2007 Wark PAB, 'Non-Invasive Ventilation in Acute Respiratory Failure', Evidence-based Respiratory Medicine 429-438 (2007)
DOI 10.1002/9780470987377.ch32
2003 Gibson PG, Wark PAB, Simpson JL, 'Induced sputum studies in children', An Atlas of Induced Sputum An Aid for Research and Diagnosis, Taylor & Francis, USA (2003)
Co-authors Jodie Simpson, Peter Gibson
Show 4 more chapters

Journal article (119 outputs)

Year Citation Altmetrics Link
2016 Tay H, Wark PAB, Bartlett NW, 'Advances in the treatment of virus-induced asthma', Expert Review of Respiratory Medicine, 10 629-641 (2016)

© 2016 Informa UK Limited, trading as Taylor & Francis Group.ABSTRACT: Viral exacerbations continue to represent the major burden in terms of morbidity, mortality and health care... [more]

© 2016 Informa UK Limited, trading as Taylor & Francis Group.ABSTRACT: Viral exacerbations continue to represent the major burden in terms of morbidity, mortality and health care costs associated with asthma. Those at greatest risk for acute asthma are those with more severe airways disease and poor asthma control. It is this group with established asthma in whom acute exacerbations triggered by virus infections remain a serious cause of increased morbidity. A range of novel therapies are emerging to treat asthma and in particular target this group with poor disease control, and in most cases their efficacy is now being judged by their ability to reduce the frequency of acute exacerbations. Critical for the development of new treatment approaches is an improved understanding of virus-host interaction in the context of the asthmatic airway. This requires research into the virology of the disease in physiological models in conjunction with detailed phenotypic characterisation of asthma patients to identify targets amenable to therapeutic intervention.

DOI 10.1080/17476348.2016.1180249
Co-authors Nathan Bartlett
2016 Haw TJ, Starkey MR, Nair PM, Pavlidis S, Liu G, Nguyen DH, et al., 'A pathogenic role for tumor necrosis factor-related apoptosis-inducing ligand in chronic obstructive pulmonary disease', Mucosal Immunology, 9 859-872 (2016) [C1]

Chronic obstructive pulmonary disease (COPD) is a life-Threatening inflammatory respiratory disorder, often induced by cigarette smoke (CS) exposure. The development of effective ... [more]

Chronic obstructive pulmonary disease (COPD) is a life-Threatening inflammatory respiratory disorder, often induced by cigarette smoke (CS) exposure. The development of effective therapies is impaired by a lack of understanding of the underlining mechanisms. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a cytokine with inflammatory and apoptotic properties. We interrogated a mouse model of CS-induced experimental COPD and human tissues to identify a novel role for TRAIL in COPD pathogenesis. CS exposure of wild-Type mice increased TRAIL and its receptor messenger RNA (mRNA) expression and protein levels, as well as the number of TRAIL + CD11b + monocytes in the lung. TRAIL and its receptor mRNA were also increased in human COPD. CS-exposed TRAIL-deficient mice had decreased pulmonary inflammation, pro-inflammatory mediators, emphysema-like alveolar enlargement, and improved lung function. TRAIL-deficient mice also developed spontaneous small airway changes with increased epithelial cell thickness and collagen deposition, independent of CS exposure. Importantly, therapeutic neutralization of TRAIL, after the establishment of early-stage experimental COPD, reduced pulmonary inflammation, emphysema-like alveolar enlargement, and small airway changes. These data provide further evidence for TRAIL being a pivotal inflammatory factor in respiratory diseases, and the first preclinical evidence to suggest that therapeutic agents that target TRAIL may be effective in COPD therapy.

DOI 10.1038/mi.2015.111
Co-authors Jay Horvat, Adam Collison, Joerg Mattes, Malcolm Starkey, Darryl Knight, Philip Hansbro, Alan Hsu, Paul Foster
2016 Conickx G, Mestdagh P, Avila Cobos F, Verhamme FM, Maes T, Vanaudenaerde BM, et al., 'MicroRNA Profiling Reveals a Role for MicroRNA-218-5p in the Pathogenesis of Chronic Obstructive Pulmonary Disease.', Am J Respir Crit Care Med, (2016)
DOI 10.1164/rccm.201506-1182OC
Co-authors Philip Hansbro, Alan Hsu
2016 Dentice RL, Elkins MR, Middleton PG, Bishop JR, Wark PA, Dorahy DJ, et al., 'A randomised trial of hypertonic saline during hospitalisation for exacerbation of cystic fibrosis.', Thorax, 71 141-147 (2016)
DOI 10.1136/thoraxjnl-2014-206716
Citations Scopus - 1Web of Science - 1
2016 Hew M, Gillman A, Sutherland M, Wark P, Bowden J, Guo M, et al., 'Real-life effectiveness of omalizumab in severe allergic asthma above the recommended dosing range criteria.', Clin Exp Allergy, (2016)
DOI 10.1111/cea.12774
Co-authors Vanessa Mcdonald, Peter Gibson
2016 Cousins JL, Wark PAB, McDonald VM, 'Acute oxygen therapy: A review of prescribing and delivery practices', International Journal of COPD, 11 1067-1075 (2016)

© 2016 Cousins et al.Oxygen is a commonly used drug in the clinical setting and like other drugs its use must be considered carefully. This is particularly true for those patient... [more]

© 2016 Cousins et al.Oxygen is a commonly used drug in the clinical setting and like other drugs its use must be considered carefully. This is particularly true for those patients who are at risk of type II respiratory failure in whom the risk of hypercapnia is well established. In recent times, several international bodies have advocated for the prescription of oxygen therapy in an attempt to reduce this risk in vulnerable patient groups. Despite this guidance, published data have demonstrated that there has been poor uptake of these recommendations. Multiple interventions have been tested to improve concordance, and while some of these interventions show promise, the sustainability of these interventions are less convincing. In this review, we summarize data that have been published on the prevalence of oxygen prescription and the accurate and appropriate administration of this drug therapy. We also identify strategies that have shown promise in facilitating changes to oxygen prescription and delivery practice. There is a clear need to investigate the barriers, facilitators, and attitudes of clinicians in relation to the prescription of oxygen therapy in acute care. Interventions based on these findings then need to be designed and tested to facilitate the application of evidence-based guidelines to support sustained changes in practice, and ultimately improve patient care.

DOI 10.2147/COPD.S103607
Citations Scopus - 1
Co-authors Vanessa Mcdonald
2016 Gang L, Hsu A, Cooley MA, Jarnicki AG, Nair PM, Haw TJ, et al., 'Fibulin-1 regulates the pathogenesis of tissue remodeling in respiratory diseases', Journal of Clinical Investigation Insight, 1 (2016)
DOI 10.1172/jci.insight.86380
Co-authors Philip Hansbro, Michael Fricker, Alan Hsu, Marjorie Walker, Darryl Knight, Jay Horvat
2016 Kim R, Pinkerton J, Essilfie A, Robertson A, Baines K, Mayall J, et al., 'NLRP3 INFLAMMASOME- MEDIATED, IL-1 beta-DEPENDENT INFLAMMATORY RESPONSES DRIVE SEVERE, STEROID-INSENSITIVE ASTHMA', RESPIROLOGY, 21 46-46 (2016)
Co-authors Jay Horvat, Philip Hansbro, Peter Gibson
2016 Hansbro P, Sunkara K, Jarnicki A, Kim R, Haw T, Wark P, et al., 'ROLE OF MIR-21 IN THE PATHOGENESIS OF EXPERIMENTAL COPD', RESPIROLOGY, 21 125-125 (2016)
Co-authors Jay Horvat, Philip Hansbro
2016 Negewo NA, McDonald VM, Baines KJ, Wark PA, Simpson JL, Jones PW, Gibson PG, 'Peripheral blood eosinophils: a surrogate marker for airway eosinophilia in stable COPD.', Int J Chron Obstruct Pulmon Dis, 11 1495-1504 (2016)
DOI 10.2147/COPD.S100338
Co-authors Jodie Simpson, Vanessa Mcdonald, Katherine Baines
2015 Wark PAB, McDonald VM, Gibson PG, 'Adjusting prednisone using blood eosinophils reduces exacerbations and improves asthma control in difficult patients with asthma.', Respirology, 20 1282-1284 (2015) [C1]
DOI 10.1111/resp.12602
Citations Scopus - 3Web of Science - 2
Co-authors Peter Gibson, Vanessa Mcdonald
2015 Vanders RL, Murphy VE, Gibson PG, Hansbro PM, Wark PAB, 'CD8 T cells and dendritic cells: Key players in the attenuated maternal immune response to influenza infection', Journal of Reproductive Immunology, 107 1-9 (2015) [C1]

© 2014 Elsevier Ireland Ltd.Pregnancy provides a unique challenge for maternal immunity, requiring the ability to tolerate the presence of a semi-allogeneic foetus, and yet still... [more]

© 2014 Elsevier Ireland Ltd.Pregnancy provides a unique challenge for maternal immunity, requiring the ability to tolerate the presence of a semi-allogeneic foetus, and yet still being capable of inducing an immune response against invading pathogens. To achieve this, numerous changes must occur in the activity and function of maternal immune cells throughout the course of pregnancy. Respiratory viruses take advantage of these changes, altering the sensitive balance of maternal immunity, leaving the mother with increased susceptibility to viral infections and increased disease severity. Influenza virus is one of the most common respiratory virus infections during pregnancy, leading to an increased risk of ICU hospitalisations, pneumonia, acute respiratory distress syndrome and even death. Whilst much research has been performed to understand the changes that must take place in maternal immunity during pregnancy, considerable work is still needed to fully comprehend this tremendous feat. To date, few studies have focused on the alterations that occur in maternal immunity during respiratory virus infections. This review highlights the role of dendritic cells (DCs) and CD8 T cells during pregnancy, and the changes that occur in these antiviral cells following influenza virus infections.

DOI 10.1016/j.jri.2014.09.051
Citations Scopus - 2Web of Science - 2
Co-authors Peter Gibson, Philip Hansbro, Vanessa Murphy
2015 Kumar RK, Shadie AM, Bucknall MP, Rutlidge H, Garthwaite L, Herbert C, et al., 'Differential injurious effects of ambient and traffic-derived particulate matter on airway epithelial cells', RESPIROLOGY, 20 73-79 (2015) [C1]
DOI 10.1111/resp.12381
Citations Scopus - 8Web of Science - 9
2015 Cheng AC, Holmes M, Senenayake S, Dwyer DE, Hewagama S, Korman T, et al., 'Influenza epidemiology in adults admitted to sentinel Australian hospitals in 2014: the Influenza Complications Alert Network (FluCAN).', Communicable diseases intelligence quarterly report, 39 E355-E360 (2015) [C1]
2015 Pathinayake PS, Hsu A, wark PA, 'Innate Immunity and Immune Evasion by Enterovirus 71', Viruses, 7 (2015) [C1]
DOI 10.3390/v7122961
Citations Web of Science - 1
Co-authors Alan Hsu
2015 Hatchwell L, Collison A, Girkin J, Parsons K, Li J, Zhang J, et al., 'Toll-like receptor 7 governs interferon and inflammatory responses to rhinovirus and is suppressed by IL-5-induced lung eosinophilia', Thorax, (2015) [C1]

© 2015 BMJ Publishing Group Ltd & British Thoracic Society.Background Asthma exacerbations represent a significant disease burden and are commonly caused by rhinovirus (RV), whic... [more]

© 2015 BMJ Publishing Group Ltd & British Thoracic Society.Background Asthma exacerbations represent a significant disease burden and are commonly caused by rhinovirus (RV), which is sensed by Toll-like receptors (TLR) such as TLR7. Some asthmatics have impaired interferon (IFN) responses to RV, but the underlying mechanisms of this clinically relevant observation are poorly understood. Objectives To investigate the importance of intact TLR7 signalling in vivo during RV exacerbation using mouse models of house dust mite (HDM)-induced allergic airways disease exacerbated by a superimposed RV infection. Methods Wild-type and TLR7-deficient (Tlr7-/-) BALB/c mice were intranasally sensitised and challenged with HDM prior to infection with RV1B. In some experiments, mice were administered recombinant IFN or adoptively transferred with plasmacytoid dendritic cells (pDC). Results Allergic Tlr7-/- mice displayed impaired IFN release upon RV1B infection, increased virus replication and exaggerated eosinophilic inflammation and airways hyper reactivity. Treatment with exogenous IFN or adoptive transfer of TLR7-competent pDCs blocked these exaggerated inflammatory responses and boosted IFN? release in the absence of host TLR7 signalling. TLR7 expression in the lungs was suppressed by allergic inflammation and by interleukin (IL)-5-induced eosinophilia in the absence of allergy. Subjects with moderate-to-severe asthma and eosinophilic but not neutrophilic airways inflammation, despite inhaled steroids, showed reduced TLR7 and IFN?2/3 expression in endobronchial biopsies. Furthermore, TLR7 expression inversely correlated with percentage of sputum eosinophils. Conclusions This implicates IL-5-induced airways eosinophilia as a negative regulator of TLR7 expression and antiviral responses, which provides a molecular mechanism underpinning the effect of eosinophil-targeting treatments for the prevention of asthma exacerbations.

DOI 10.1136/thoraxjnl-2014-205465
Citations Scopus - 9Web of Science - 12
Co-authors Darryl Knight, Adam Collison, Nathan Bartlett, Paul Foster, Joerg Mattes
2015 Hsu ACY, Starkey MR, Hanish I, Parsons K, Haw TJ, Howland LJ, et al., 'Targeting PI3K-p110a suppresses influenza virus infection in chronic obstructive pulmonary disease', American Journal of Respiratory and Critical Care Medicine, 191 1012-1023 (2015) [C1]

Copyright © 2015 by the American Thoracic Society.Rationale: Chronic obstructive pulmonary disease (COPD) and influenza virus infections are major global health issues. Patients ... [more]

Copyright © 2015 by the American Thoracic Society.Rationale: Chronic obstructive pulmonary disease (COPD) and influenza virus infections are major global health issues. Patients with COPD are more susceptible to infection, which exacerbates their condition and increases morbidity and mortality. The mechanisms of increased susceptibility remain poorly understood, and current preventions and treatments have substantial limitations. Objectives: To characterize the mechanisms of increased susceptibility to influenza virus infection in COPD and the potential for therapeutic targeting. Methods: We used a combination of primary bronchial epithelial cells (pBECs) from COPD and healthy control subjects, a mouse model of cigarette smoke-induced experimental COPD, and influenza infection. The role of the phosphoinositide-3-kinase (PI3K) pathway was characterized using molecular methods, and its potential for targeting assessed using inhibitors. Measurements and Main Results: COPDpBECs were susceptible to increased viral entry and replication. Infected mice with experimental COPD also had more severe infection (increased viral titer and pulmonary inflammation, and compromised lung function). These processes were associated with impaired antiviral immunity, reduced retinoic acid-inducible gene-I, and IFN/cytokine and chemokine responses. Increased PI3K-p110a levels and activity inCOPDpBECs and/or mice were responsible for increased infection and reduced antiviral responses. Global PI3K, specific therapeutic p110a inhibitors, or exogenous IFN-b restored protective antiviral responses, suppressed infection, and improved lung function. Conclusions: The increased susceptibility of individuals with COPD to influenza likely results from impaired antiviral responses, which are mediated by increased PI3K-p110a activity. This pathway may be targeted therapeutically in COPD, or in healthy individuals, during seasonal or pandemic outbreaks to prevent and/or treat influenza.

DOI 10.1164/rccm.201501-0188OC
Citations Scopus - 12Web of Science - 12
Co-authors Malcolm Starkey, Alan Hsu, Darryl Knight, Philip Hansbro, Paul Foster
2015 Carlet J, Aaron L, Abassi MS, Abbo L, Aboderin O, Abraham E, et al., 'World alliance against antibiotic resistance: The WAAAR declaration against antibiotic resistance', Medicina Intensiva, 39 34-39 (2015)

© 2014 Elsevier España, S.L.U. and SEMICYUC.We must change how antibiotics are used and adopt proactive strategies, similar to those used to save endangered species. Preservatio... [more]

© 2014 Elsevier España, S.L.U. and SEMICYUC.We must change how antibiotics are used and adopt proactive strategies, similar to those used to save endangered species. Preservation of the efficacy of antibiotics and to stabilization of antibiotic-susceptible bacterial ecosystems should be global goals.

DOI 10.1016/j.medin.2014.10.004
Citations Scopus - 1
2015 Kidd TJ, Magalhães RJS, Paynter S, Bell SC, Grimwood K, Armstrong DS, et al., 'The social network of cystic fibrosis centre care and shared Pseudomonas aeruginosa strain infection: A cross-sectional analysis', The Lancet Respiratory Medicine, 3 640-650 (2015)

© 2015 Elsevier Ltd.Background: Person-to-person transmission is a potential pathway of Pseudomonas aeruginosa acquisition in cystic fibrosis. Reports of cross-infection of share... [more]

© 2015 Elsevier Ltd.Background: Person-to-person transmission is a potential pathway of Pseudomonas aeruginosa acquisition in cystic fibrosis. Reports of cross-infection of shared cystic-fibrosis-specific P aeruginosa strains across large geographical distances are concerning. Therefore, we aimed to assess the extent to which patient movement between cystic fibrosis centres contributes to dissemination. Methods: We did a cross-sectional study to assess movement of patients with cystic fibrosis who were infected with P aeruginosa between Sept 3, 2007, and June 16, 2010, at 18 Australian cystic fibrosis centres. We applied social network analysis to patient movement data from P aeruginosa-infected patients to assess the role of patient mobility in P aeruginosa genotype prevalence. We generated networks linking treatment centres based on the movement of patients attending adult and paediatric cystic fibrosis centres, and compared these with the movement of patients infected with all P aeruginosa strains, unique strains, and predominant Australian shared strains (AUST-01 and AUST-02). We summarised connectivity using degree centrality, in-degree centrality, out-degree centrality, and k-core estimates. Infection control and surveillance practices were also assessed by use of a questionnaire. Findings: 983 patients (mean age 25 years [SD 10]; 551 [56%] male) provided 2887 P aeruginosa isolates for ERIC-PCR genotyping, which yielded 531 distinct genotypes: 493 unique strains in 373 patients and 38 shared strains in 610 patients. AUST-01 infections were associated with higher in-degree centrality (p=0·004) and k-core (p=0·005) estimates and AUST-02 infections with higher degree centrality (p=0·002), out-degree centrality (p=0·002), and k-core (p=0·007) estimates for the previous health-care facilities; associations for the present cystic fibrosis centre were not significant. These findings were significant for adult patients (AUST-01 in-degree centrality p=0·004 and k-core p=0·005; AUST-02 degree centrality p=0·004, out-degree centrality p=0·003, and k-core p=0·007), but not for paediatric patients. By contrast, infections with unique strains were associated with a lower k-core estimate for the present cystic fibrosis centre overall (p<0·0001); this finding was significant in adults (p<0·0001), but not in paediatric patients. Interpretation: Our results show that the connectivity of cystic fibrosis centres, as measured by the movement of patients, seems to be an important risk factor for the acquisition of shared P aeruginosa strain infections. These results show the importance of prioritising infection control interventions (eg, prospective molecular surveillance for shared P aeruginosa strains, strict universal infection control precautions, and hospital design and ventilation) to limit P aeruginosa cross-infection between patients with cystic fibrosis. Funding: Australian National Health and Medical Research Council; Children's Health Foundation Queensland; Office of Health and Medical Research, Queensland Health; European Respiratory Society-European Union; Australian Cystic Fibrosis Research Trust; Prince Charles Hospital Foundation; and Rotary Australia.

DOI 10.1016/S2213-2600(15)00228-3
Citations Scopus - 2
2015 Cheng AC, Kotsimbos T, Kelly PM, Wark P, Hunter C, Hewagama S, et al., 'Influenza vaccine effectiveness against hospitalisation with influenza in adults in Australia in 2014', Vaccine, 33 7352-7356 (2015) [C1]

© 2015 Elsevier Ltd.We provide estimates of the influenza vaccine protection against hospitalisation with laboratory-confirmed influenza in the 2014 Australian season where the A... [more]

© 2015 Elsevier Ltd.We provide estimates of the influenza vaccine protection against hospitalisation with laboratory-confirmed influenza in the 2014 Australian season where the A/H1N1/pdm09 strain predominated. This was performed using a case-test negative study design as part of a national sentinel surveillance system in Australia. Vaccine effectiveness was estimated as (1-OR). ×. 100% where the odds ratio of vaccination in cases vs test negative participants was estimated from a conditional logistic regression. Between April and November, 1692 adult patients were admitted with laboratory-confirmed influenza. Vaccine effectiveness was estimated from 1283 patients with influenza and 1116 test negative patients where vaccination status was ascertained. Vaccination was associated with a reduction in the risk of hospitalisation with influenza of 51.5% (95% CI: 41.6%, 59.7%) in all patients, and a reduction of 50.7% (95% CI: 40.1%, 59.3%) in the target population for vaccination. We estimate that the influenza vaccine was moderately protective against hospitalisation with laboratory-confirmed influenza during the 2014 influenza season in Australia.

DOI 10.1016/j.vaccine.2015.10.016
2015 Tolosa JM, Parsons KS, Hansbro PM, Smith R, Wark PB, 'The placental protein syncytin-1 impairs antiviral responses and exaggerates inflammatory responses to influenza', PLoS ONE, 10 (2015) [C1]

© 2015 Tolosa et al.Background Pregnancy increases susceptibility to influenza. The placenta releases an immunosuppressive endogenous retroviral protein syncytin-1.We hypothesise... [more]

© 2015 Tolosa et al.Background Pregnancy increases susceptibility to influenza. The placenta releases an immunosuppressive endogenous retroviral protein syncytin-1.We hypothesised that exposure of peripheral monocytes (PBMCs) to syncytin-1 would impair responses to H1N1pdm09 influenza. Methods and Findings Recombinant syncytin-1 was produced. PBMCs from non-pregnant women (n=10) were exposed to H1N1pdm09 in the presence and absence of syncytin-1 and compared to responses of PBMCs from pregnant women (n=12). PBMCs were characterised using flow cytometry, release of interferon (IFN)-a, IFN-¿, IFN-¿, IL-10, IL-2, IL-6 and IL-1ß were measured by cytometric bead array or ELISA. Exposure of PBMCs to H1N1pdm09 resulted in the release of IFN-a, (14,787 pg/mL, 95% CI 7311-22,264 pg/mL) IFN-¿ (1486 pg/mL, 95% CI 756-2216 pg/mL) and IFN-¿ (852 pg/mL, 95% CI 193-1511 pg/mL) after 48 hours. This was significantly impaired in pregnant women (IFN-a; p<0.0001 and IFN-¿; p<0.001). Furthermore, in the presence of syncytin-1, PBMCs demonstrated marked reductions in IFN-a and IFN-¿, while enhanced release of IL-10 as well as IL-6 and IL-1ß. Conclusions Our data indicates that a placental derived protein, syncytin-1 may be responsible for the heightened vulnerability of pregnant women to influenza.

DOI 10.1371/journal.pone.0118629
Citations Scopus - 5Web of Science - 4
Co-authors Philip Hansbro, Roger Smith
2015 Baines KJ, Wright TK, Simpson JL, McDonald VM, Wood LG, Parsons KS, et al., 'Airway beta-Defensin-1 Protein Is Elevated in COPD and Severe Asthma', MEDIATORS OF INFLAMMATION, (2015) [C1]
DOI 10.1155/2015/407271
Citations Scopus - 2Web of Science - 2
Co-authors Peter Gibson, Lisa Wood, Katherine Baines, Jodie Simpson, Vanessa Mcdonald
2014 Djukanovic R, Harrison T, Johnston SL, Gabbay F, Wark P, Thomson NC, et al., 'The Effect of Inhaled IFN-beta on Worsening of Asthma Symptoms Caused by Viral Infections A Randomized Trial', AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 190 145-154 (2014) [C1]
DOI 10.1164/rccm.201312-2235OC
Citations Scopus - 47Web of Science - 36
2014 Cheng AC, Dwyer DE, Holmes M, Irving LB, Brown SGA, Waterer GW, et al., 'Influenza epidemiology, vaccine coverage and vaccine effectiveness in sentinel Australian hospitals in 2013: the Influenza Complications Alert Network', Communicable diseases intelligence quarterly report, 38 E143-E149 (2014)

This work is copyright. You may download, display, print and reproduce the whole or part of this work in unaltered form for your own personal use or, if you are part of an organis... [more]

This work is copyright. You may download, display, print and reproduce the whole or part of this work in unaltered form for your own personal use or, if you are part of an organisation, for internal use within your organisation, but only if you or your organisation do not use the reproduction for any commercial purpose and retain this copyright notice and all disclaimer notices as part of thatThe National Influenza Program aims to reduce serious morbidity and mortality from influenza by providing public funding for vaccination to at-risk groups. The Influenza Complications Alert Network (FluCAN) is a sentinel hospital-based surveillance program that operates at 14 sites in all states and territories in Australia. This report summarises the epidemiology of hospitalisations with confirmed influenza, estimates vaccine coverage and influenza vaccine protection against hospitalisation with influenza during the 2013 influenza season. In this observational study, cases were defined as patients admitted to one of the sentinel hospitals, with influenza confirmed by nucleic acid testing. Controls were patients who had acute respiratory illnesses who were test-negative for influenza. Vaccine effectiveness was estimated as 1 minus the odds ratio of vaccination in case patients compared with control patients, after adjusting for known confounders. During the period 5 April to 31 October 2012, 631 patients were admitted with confirmed influenza at the 14 FluCAN sentinel hospitals. Of these, 31% were more than 65 years of age, 9.5% were Indigenous Australians, 4.3% were pregnant and 77% had chronic co-morbidities. Influenza B was detected in 30% of patients. Vaccination coverage was estimated at 81% in patients more than 65 years of age but only 49% in patients aged less than 65 years with chronic comorbidities. Vaccination effectiveness against hospitalisation with influenza was estimated at 50% (95% confidence interval: 33%, 63%, P<0.001). We detected a significant number of hospital admissions with confirmed influenza in a national observational study. Vaccine coverage was incomplete in at-risk groups, particularly non-elderly patients with medical comorbidities. Our results suggest that the seasonal influenza vaccine was moderately protective against hospitalisation with influenza in the 2013 season.

Citations Scopus - 4
2014 Wark PAB, Murphy V, Mattes J, 'The interaction between mother and fetus and the development of allergic asthma', Expert Review of Respiratory Medicine, 8 57-66 (2014) [C1]

The rising prevalence of asthma and atopic disease in industrialized countries in the last 50 years has raised important questions about how and why the disease develops in suscep... [more]

The rising prevalence of asthma and atopic disease in industrialized countries in the last 50 years has raised important questions about how and why the disease develops in susceptible populations. Most asthma begins in childhood in association with allergic sensitization and the development of a TH2 phenotype. It is recognized that asthma arises in the context of a complex interaction between genetic factors and the evolving immune system of the infant and the environment to which it is exposed, which now includes its in utero exposure. Early life exposures that lead to allergen sensitization and airway damage, especially in the form of viral respiratory tract infections, may lead to disease induction that commence the process that leads in some to asthma. Asthma models and early life observations suggest that repeated exposure to allergens and viral infection perpetuate a state of chronic airway inflammation leading to a maladaptive innate immune response that fails to resolve, characterized by chronic airway inflammation, airway remodeling and airway hyperresponsiveness. This article will concentrate on the development of asthma in the context of early life and maternal influences, including the effect of asthma on both the fetus and the mother. © 2014 Informa UK Ltd.

DOI 10.1586/17476348.2014.848795
Citations Scopus - 4Web of Science - 4
Co-authors Vanessa Murphy, Joerg Mattes
2014 Parsons KS, Hsu AC, Wark PAB, 'TLR3 and MDA5 signalling, although not expression, is impaired in asthmatic epithelial cells in response to rhinovirus infection', Clinical and Experimental Allergy, 44 91-101 (2014) [C1]

Summary: Background: Rhinoviruses (RV) are the most common acute triggers of asthma, and airway epithelial cells are the primary site of infection. Asthmatic bronchial epithelial ... [more]

Summary: Background: Rhinoviruses (RV) are the most common acute triggers of asthma, and airway epithelial cells are the primary site of infection. Asthmatic bronchial epithelial cells (BECs) have been found to have impaired innate immune responses to RV. RV entry and replication is recognized by pathogen recognition receptors (PRRs), specifically toll-like receptor (TLR)3 and the RNA helicases; retinoic acid-inducible gene I (RIG-I) and melanoma differentiation-associated gene 5 (MDA5). Objective: Our aim was to assess the relative importance of these PRRs in primary bronchial epithelial cells (pBEC) from healthy controls and asthmatics following RV infection and determine whether deficient innate immune responses in asthmatic pBECs were due to abnormal signalling via these PRRs. Methods: The expression patterns and roles of TLR3 and MDA5 were investigated using siRNA knock-down, with subsequent RV1B infection in pBECs from each patient group. We also used BX795, a specific inhibitor of TBK1 and IKKi. Results: Asthmatic pBECs had significantly reduced release of IL-6, CXCL-8 and IFN-¿ in response to RV1B infection compared with healthy pBECs. In healthy pBECs, siMDA5, siTLR3 and BX795 all reduced release of IL-6, CXCL-10 and IFN-¿ to infection. In contrast, in asthmatic pBECs where responses were already reduced, there was no further reduction in IL-6 and IFN-¿, although there was in CXCL-10. Conclusion and Clinical Relevance: Impaired antiviral responses in asthmatic pBECs are not due to deficient expression of PRRs; MDA5 and TLR3, but an inability to later activate types I and III interferon immune responses to RV infection, potentially increasing susceptibility to the effects of RV infection. © 2013 John Wiley & Sons Ltd.

DOI 10.1111/cea.12218
Citations Scopus - 14Web of Science - 14
Co-authors Alan Hsu
2013 Murphy VE, Powell H, Wark PAB, Gibson PG, 'A Prospective Study of Respiratory Viral Infection in Pregnant Women With and Without Asthma', CHEST, 144 420-427 (2013) [C1]
DOI 10.1378/chest.12-1956
Citations Scopus - 7Web of Science - 3
Co-authors Peter Gibson, Vanessa Murphy
2013 Hansbro P, Beckett E, Stevens R, Jarnicki A, Wark P, Foster P, 'A short-term model of COPD identifies a role for mast cell tryptase', EUROPEAN RESPIRATORY JOURNAL, 42 (2013)
Co-authors Philip Hansbro, Paul Foster, Simon Keely, Jay Horvat
2013 Vanders RL, Gibson PG, Murphy VE, Wark PAB, 'Plasmacytoid Dendritic Cells and CD8 T Cells From PregnantWomen Show Altered Phenotype and Function Following H1N1/09 Infection', JOURNAL OF INFECTIOUS DISEASES, 208 1062-1070 (2013) [C1]
DOI 10.1093/infdis/jit296
Citations Scopus - 7Web of Science - 5
Co-authors Peter Gibson, Vanessa Murphy
2013 Beckett EL, Stevens RL, Jarnicki AG, Kim RY, Hanish I, Hansbro NG, et al., 'A new short-term mouse model of chronic obstructive pulmonary disease identifies a role for mast cell tryptase in pathogenesis', The Journal of Allergy and Clinical Immunology, 131 752-762 (2013) [C1]
Citations Scopus - 50Web of Science - 50
Co-authors Paul Foster, Jay Horvat, Ming Yang, Nicole Hansbro, Simon Keely, Philip Hansbro
2013 Kidd TJ, Ramsay KA, Hu H, Marks GB, Wainwright CE, Bye PT, et al., 'Shared Pseudomonas aeruginosa genotypes are common in Australian cystic fibrosis centres', European Respiratory Journal, 41 1091-1100 (2013)

Recent molecular-typing studies suggest cross-infection as one of the potential acquisition pathways for Pseudomonas aeruginosa in patients with cystic fibrosis (CF). In Australia... [more]

Recent molecular-typing studies suggest cross-infection as one of the potential acquisition pathways for Pseudomonas aeruginosa in patients with cystic fibrosis (CF). In Australia, there is only limited evidence of unrelated patients sharing indistinguishable P. aeruginosa strains. We therefore examined the point-prevalence, distribution, diversity and clinical impact of P. aeruginosa strains in Australian CF patients nationally. 983 patients attending 18 Australian CF centres provided 2887 sputum P. aeruginosa isolates for genotyping by enterobacterial repetitive intergenic consensus-PCR assays with confirmation by multilocus sequence typing. Demographic and clinical details were recorded for each participant. Overall, 610 (62%) patients harboured at least one of 38 shared genotypes. Most shared strains were in small patient clusters from a limited number of centres. However, the two predominant genotypes, AUST-01 and AUST-02, were widely dispersed, being detected in 220 (22%) and 173 (18%) patients attending 17 and 16 centres, respectively. AUST-01 was associated with significantly greater treatment requirements than unique P. aeruginosa strains. Multiple clusters of shared P. aeruginosa strains are common in Australian CF centres. At least one of the predominant and widespread genotypes is associated with increased healthcare utilisation. Longitudinal studies are now needed to determine the infection control implications of these findings. Copyright ©ERS 2013.

DOI 10.1183/09031936.00060512
Citations Scopus - 22
2013 Collison AM, Hatchwell LM, Verrills NM, Wark PA, Pereira De Siqueira AL, Tooze MK, et al., 'The E3 ubiquitin ligase midline 1 promotes allergen and rhinovirus-induced asthma by inhibiting protein phosphatase 2A activity', Nature Medicine, 19 232-237 (2013) [C1]
Citations Scopus - 48Web of Science - 43
Co-authors Joerg Mattes, Nikki Verrills, Paul Foster, Adam Collison, Nathan Bartlett
2013 Frith P, Thompson P, Wark P, Lindstrom S, Bateman E, 'BENEFITS OF DUAL BRONCHODILATION WITH QVA149 ONCE DAILY VERSUS PLACEBO, INDACATEROL, NVA237 AND TIOTROPIUM IN PATIENTS WITH COPD: THE SHINE STUDY', RESPIROLOGY, 18 20-20 (2013)
Citations Web of Science - 2
2013 Cheng AC, Brown S, Waterer G, Holmes M, Senenayake S, Friedman ND, et al., 'Influenza epidemiology, vaccine coverage and vaccine effectiveness in sentinel Australian hospitals in 2012: the Influenza Complications Alert Network (FluCAN)', Communicable diseases intelligence quarterly report, 37 E246-E252 (2013)

This work is copyright. Apart from any use as permitted under the Copyright Act 1968, no part may be reproduced by any process without prior written permission from the Commonweal... [more]

This work is copyright. Apart from any use as permitted under the Copyright Act 1968, no part may be reproduced by any process without prior written permission from the Commonwealth. Requests and inquiries concerning reproduction and rights should be addressed to the Commonwealth Copyright Administration, Attorney General's Department, Robert Garran Offices, National Circuit, Barton ACT 2600 orInfluenza is mostly a mild, self-limiting infection and severe infection requiring hospitalisation is uncommon. Immunisation aims to reduce serious morbidity and mortality. The Influenza Complications Alert Network (FluCAN) is a sentinel hospital-based surveillance program that operates at 15 sites across all states and territories in Australia. This study reports on the epidemiology of hospitalisation with confirmed influenza, estimate vaccine coverage and influenza vaccine protection against hospitalisation with influenza during the 2012 influenza season. In this observational study, cases were defined as patients admitted to one of the sentinel hospitals with influenza confirmed by nucleic acid detection. Controls were patients who had acute respiratory illnesses who were test-negative for influenza. Vaccine effectiveness was estimated as 1¿minus the odds ratio of vaccination in case patients compared with control patients, after adjusting for known confounders. During the period 9 April to 31 October 2012, 1,231 patients were admitted with confirmed influenza at the 15 FluCAN sentinel hospitals. Of these, 47% were more than 65 years of age, 8% were Indigenous Australians, 3% were pregnant and 76% had chronic co-morbidities. Influenza A was detected in 83% of patients. Vaccination coverage was calculated from the vaccination status of 1,216 test negative controls and was estimated at 77% in patients 65 years or over and 61% in patients with chronic comorbidities. Vaccination effectiveness was estimated at 41% (95% CI: 28%, 51%, P<0.001). Vaccine coverage was incomplete in at-risk groups, particularly non-elderly patients with medical comorbidities. The study results suggest that the seasonal influenza vaccine was moderately protective against hospitalisation with influenza during the 2012 season.

Citations Scopus - 5
2013 Vanders RL, Gibson PG, Wark PAB, Murphy VE, 'Alterations in inflammatory, antiviral and regulatory cytokine responses in peripheral blood mononuclear cells from pregnant women with asthma', RESPIROLOGY, 18 827-833 (2013) [C1]
DOI 10.1111/resp.12068
Citations Scopus - 8Web of Science - 5
Co-authors Vanessa Murphy, Peter Gibson
2013 Wark PAB, Tooze M, Powell H, Parsons K, 'Viral and bacterial infection in acute asthma and chronic obstructive pulmonary disease increases the risk of readmission', RESPIROLOGY, 18 996-1002 (2013) [C1]
DOI 10.1111/resp.12099
Citations Scopus - 24Web of Science - 19
2013 Baines KJ, Hsu AC-Y, Tooze M, Gunawardhana LP, Gibson PG, Wark PAB, 'Novel immune genes associated with excessive inflammatory and antiviral responses to rhinovirus in COPD', RESPIRATORY RESEARCH, 14 (2013) [C1]
DOI 10.1186/1465-9921-14-15
Citations Scopus - 13Web of Science - 14
Co-authors Peter Gibson, Alan Hsu, Katherine Baines
2013 Cheng AC, Holmes M, Irving LB, Brown SGA, Waterer GW, Korman TM, et al., 'Influenza Vaccine Effectiveness against Hospitalisation with Confirmed Influenza in the 2010-11 Seasons: A Test-negative Observational Study', PLOS ONE, 8 (2013) [C1]
DOI 10.1371/journal.pone.0068760
Citations Scopus - 20Web of Science - 14
2012 Sukkar MB, Ullah MA, Gan WJ, Wark PA, Chung KF, Hughes JM, et al., 'RAGE: a new frontier in chronic airways disease', British Journal of Pharmacology, 167 1161-1176 (2012) [C1]
Citations Scopus - 27Web of Science - 20
2012 Hurt AC, Hardie K, Wilson NJ, Deng YM, Osbourn M, Leang SK, et al., 'Characteristics of a widespread community cluster of H275Y Oseltamivir-Resistant A (H1N1)pdm09 influenza in Australia', Journal of Infectious Diseases, 206 148-157 (2012) [C1]
Citations Scopus - 67Web of Science - 61
Co-authors David Durrheim, Craig Dalton
2012 Vanders RL, Wark PA, Murphy VE, Gibson PG, 'Pregnant women have attenuated innate interferon responses to 2009 pandemic influenza a virus subtype H1N1', Journal of Infectious Diseases, 206 646-653 (2012) [C1]
Citations Scopus - 18Web of Science - 17
Co-authors Vanessa Murphy, Peter Gibson
2012 Bozinovski S, Uddin M, Vlahos R, Thompson M, McQualter JL, Merritt A-S, et al., 'Serum amyloid A opposes lipoxin A(4) to mediate glucocorticoid refractory lung inflammation in chronic obstructive pulmonary disease', Proceedings of the National Academy of Sciences of the United States of America, 109 935-940 (2012) [C1]
DOI 10.1073/pnas.1109382109
Citations Scopus - 50Web of Science - 51
2012 Vanders RL, Gibson PG, Murphy VE, Wark PAB, 'Impaired type I and III interferon response to rhinovirus infection during pregnancy and asthma', Thorax, 67 209-214 (2012) [C1]
Citations Scopus - 32Web of Science - 26
Co-authors Peter Gibson, Vanessa Murphy
2012 Sukkar MB, Wood LG, Tooze MK, Simpson JL, McDonald VM, Gibson PG, Wark PA, 'Soluble RAGE is deficient in neutrophilic asthma and COPD', European Respiratory Journal, 39 721-729 (2012) [C1]
Co-authors Jodie Simpson, Peter Gibson, Lisa Wood, Vanessa Mcdonald
2012 Wark PA, Tooze M, Cheese L, Whitehead BF, Gibson PG, Wark K, McDonald VM, 'Viral infections trigger exacerbations of cystic fibrosis in adults and children', European Respiratory Journal, 40 510-512 (2012) [C1]
DOI 10.1183/09031936.00202311
Citations Scopus - 10Web of Science - 11
Co-authors Vanessa Mcdonald, Peter Gibson
2012 Ryan NM, Vertigan AE, Ferguson JK, Wark PA, Gibson PG, 'Clinical and physiological features of postinfectious chronic cough associated with H1N1 infection', Respiratory Medicine, 106 138-144 (2012) [C1]
DOI 10.1016/j.rmed.2011.10.007
Citations Scopus - 7Web of Science - 7
Co-authors Nicole Ryan, Peter Gibson, John Ferguson
2012 Wark PA, 'Airway inflammation in asthma, a single measurement is not enough', Respirology, 17 393-394 (2012) [C3]
Citations Scopus - 1Web of Science - 1
2012 Hsu A, See HV, Hansbro PM, Wark PA, 'Innate immunity to influenza in chronic airways diseases', Respirology, 17 1166-1175 (2012) [C1]
Citations Scopus - 12Web of Science - 10
Co-authors Alan Hsu, Philip Hansbro
2012 Pretto JJ, McDonald VM, Wark PA, Hensley MJ, 'Multicentre audit of inpatient management of acute exacerbations of chronic obstructive pulmonary disease: Comparison with clinical guidelines', Internal Medicine Journal, 42 380-387 (2012) [C1]
DOI 10.1111/j.1445-5994.2011.02475.x
Citations Scopus - 13Web of Science - 15
Co-authors Vanessa Mcdonald, Michael Hensley
2012 Vlahos R, Wark PAB, Anderson GP, Bozinovski S, 'Glucocorticosteroids Differentially Regulate MMP-9 and Neutrophil Elastase in COPD', PLOS ONE, 7 (2012) [C1]
DOI 10.1371/journal.pone.0033277
Citations Scopus - 33Web of Science - 29
2012 Hsu A, Parsons KS, Barr I, Lowther S, Middleton D, Hansbro PM, Wark PA, 'Critical role of constitutive type I interferon response in bronchial epithelial cell to influenza infection', PLoS One, 7 e32947 (2012) [C1]
DOI 10.1371/journal.pone.0032947
Citations Scopus - 24Web of Science - 26
Co-authors Philip Hansbro, Alan Hsu
2011 Wark PA, 'Tiotropium reduced exacerbations more than salmeterol in moderate-to-very severe COPD', Annals of Internal Medicine, 155 3 (2011) [C3]
2011 Cheng AC, Kotsimbos T, Kelly HA, Irving LB, Bowler SD, Brown SGA, et al., 'Effectiveness of H1N1/09 monovalent and trivalent influenza vaccines against hospitalization with laboratory-confirmed H1N1/09 influenza in Australia: A test-negative case control study', Vaccine, 29 7320-7325 (2011) [C1]
DOI 10.1016/j.vaccine.2011.07.087
Citations Scopus - 31Web of Science - 27
2011 Wood LG, Simpson JL, Wark PA, Powell H, Gibson PG, 'Characterization of innate immune signalling receptors in virus-induced acute asthma', Clinical and Experimental Allergy, 41 640-648 (2011) [C1]
DOI 10.1111/j.1365-2222.2010.03669.x
Citations Scopus - 17Web of Science - 16
Co-authors Lisa Wood, Jodie Simpson, Peter Gibson
2011 Katelaris CH, Linneberg A, Magnan A, Thomas WR, Wardlaw AJ, Wark PA, 'Developments in the field of allergy in 2010 through the eyes of Clinical and Experimental Allergy', Clinical and Experimental Allergy, 41 1690-1710 (2011) [C3]
DOI 10.1111/j.1365-2222.2011.03892.x
Citations Scopus - 6Web of Science - 6
2011 Hsu A, Barr I, Hansbro PM, Wark PA, 'Human influenza is more effective than Avian influenza at antiviral suppression in airway cells', American Journal of Respiratory Cell and Molecular Biology, 44 906-913 (2011) [C1]
DOI 10.1165/rcmb.2010-0157OC
Citations Scopus - 16Web of Science - 14
Co-authors Philip Hansbro, Alan Hsu
2010 Wood LG, Wark PA, Garg ML, 'Antioxidant and anti-inflammatory effects of resveratrol in airway disease', Antioxidants & Redox Signaling, 13 1535-1548 (2010) [C1]
DOI 10.1089/ars.2009.3064
Citations Scopus - 50Web of Science - 50
Co-authors Manohar Garg, Lisa Wood
2010 Wark PA, 'Viral and bacterial interactions in pneumonia', Expert Review of Respiratory Medicine, 4 221-228 (2010) [C1]
DOI 10.1586/ers.10.5
Citations Scopus - 5
2010 Reddel HK, Gibson PG, Peters MJ, Wark PA, Sand IB, Hoyos CM, Jenkins CR, 'Down-titration from high-dose combination therapy in asthma: Removal of long-acting b2-agonist', Respiratory Medicine, 104 1110-1120 (2010) [C1]
DOI 10.1016/j.rmed.2010.04.003
Citations Scopus - 37Web of Science - 34
Co-authors Peter Gibson
2010 Osei-Kumah A, Wark PA, Smith R, Clifton VL, 'Asthma during pregnancy alters immune cell profile and airway epithelial chemokine release', Inflammation Research, 59 349-358 (2010) [C1]
DOI 10.1007/s00011-009-0102-y
Citations Scopus - 7Web of Science - 6
Co-authors Vicki Clifton, Roger Smith
2009 Wark PA, McDonald VM, 'Nebulised hypertonic saline for cystic fibrosis', Cochrane Database of Systematic Reviews, - CD001506 (2009) [C1]
DOI 10.1002/14651858.cd001506.pub3
Citations Scopus - 70Web of Science - 41
Co-authors Vanessa Mcdonald
2009 Saedi Some Olia A, Wood LG, Garg ML, Gibson PG, Wark PA, 'Anti-inflammatory effects of long-chain n-3 PUFA in rhinovirus-infected cultured airway epithelial cells', British Journal of Nutrition, 101 533-540 (2009) [C1]
DOI 10.1017/s0007114508025798
Citations Scopus - 16Web of Science - 13
Co-authors Peter Gibson, Manohar Garg, Lisa Wood
2009 Kidd TJ, Ramsay KA, Hu H, Bye PTP, Elkins MR, Grimwood K, et al., 'Low rates of Pseudomonas aeruginosa misidentification in isolates from cystic fibrosis patients', Journal of Clinical Microbiology, 47 1503-1509 (2009)

Pseudomonas aeruginosa is an important cause of pulmonary infection in cystic fibrosis (CF). Its correct identification ensures effective patient management and infection control ... [more]

Pseudomonas aeruginosa is an important cause of pulmonary infection in cystic fibrosis (CF). Its correct identification ensures effective patient management and infection control strategies. However, little is known about how often CF sputum isolates are falsely identified as P. aeruginosa. We used P. aeruginosa-specific duplex real-time PCR assays to determine if 2,267 P. aeruginosa sputum isolates from 561 CF patients were correctly identified by 17 Australian clinical microbiology laboratories. Misidentified isolates underwent further phenotypic tests, amplified rRNA gene restriction analysis, and partial 16S rRNA gene sequence analysis. Participating laboratories were surveyed on how they identified P. aeruginosa from CF sputum. Overall, 2,214 (97.7%) isolates from 531 (94.7%) CF patients were correctly identified as P. aeruginosa. Further testing with the API 20NE kit correctly identified only 34 (59%) of the misidentified isolates. Twelve (40%) patients had previously grown the misidentified species in their sputum. Achromobacter xylosoxidans (n = 21), Stenotrophomonas maltophilia (n = 15), and Inquilinus limosus (n = 4) were the species most commonly misidentified as P. aeruginosa. Overall, there were very low rates of P. aeruginosa misidentification among isolates from a broad cross section of Australian CF patients. Additional improvements are possible by undertaking a culture history review, noting colonial morphology, and performing stringent oxidase, DNase, and colistin susceptibility testing for all presumptive P. aeruginosa isolates. Isolates exhibiting atypical phenotypic features should be evaluated further by additional phenotypic or genotypic identification techniques. Copyright © 2009, American Society for Microbiology. All Rights Reserved.

DOI 10.1128/JCM.00014-09
Citations Scopus - 28
2009 Saedi Some Olia A, Wood LG, Garg ML, Gibson PG, Wark PA, 'Lycopene enrichment of cultured airway epithelial cells decreases the inflammation induced by rhinovirus infection and lipopolysaccharide', Journal of Nutritional Biochemistry, 20 577-585 (2009) [C1]
DOI 10.1016/j.jnutbio.2008.06.001
Citations Scopus - 30Web of Science - 27
Co-authors Manohar Garg, Peter Gibson, Lisa Wood
2009 Wark PA, Grissell TV, Davies BL, See HV, Gibson PG, 'Diversity in the bronchial epithelial cell response to infection with different rhinovirus strains', Respirology, 14 180-186 (2009) [C1]
DOI 10.1111/j.1440-1843.2009.01480.x
Citations Scopus - 47Web of Science - 45
Co-authors Peter Gibson
2008 Saedi Some Olia A, Wood LG, Garg ML, Gibson PG, Wark PA, 'Supplementation of long chain N-3 polyunsaturated fatty acids increases the utilization of lycopene in cultured airway epithelial cells', Journal of Food Lipids, 15 421-432 (2008) [C1]
DOI 10.1111/j.1745-4522.2008.00130.x
Citations Scopus - 7Web of Science - 5
Co-authors Lisa Wood, Peter Gibson, Manohar Garg
2008 Wark PA, 'Guest editorial', Paediatric Respiratory Reviews, 9 233-235 (2008) [C3]
DOI 10.1016/j.prrv.2008.05.006
2008 See HV, Wark PA, 'Innate immune response to viral infection of the lungs', Paediatric Respiratory Reviews, 9 243-250 (2008) [C1]
DOI 10.1016/j.prrv.2008.04.001
Citations Scopus - 31Web of Science - 27
2008 Simpson JL, Wark PA, 'The role of exhaled nitric oxide and exhaled breath condensates in evaluating airway inflammation in asthma', Expert Opinion on Medical Diagnostics, 2 607-620 (2008) [C1]
DOI 10.1517/17530059.2.6.607
Citations Scopus - 2
Co-authors Jodie Simpson
2008 Oliver BGG, Lim S, Wark PA, Laza-Stanca V, King N, Black JL, et al., 'Rhinovirus exposure impairs immune responses to bacterial products in human alveolar macrophages', Thorax, 63 519-525 (2008) [C1]
DOI 10.1136/thx.2007.081752
Citations Scopus - 66Web of Science - 58
2008 Hansbro NG, Horvat JC, Wark PA, Hansbro PM, 'Understanding the mechanisms of viral induced asthma: New therapeutic directions', Pharmacology & Therapeutics, 117 313-353 (2008) [C1]
DOI 10.1016/j.pharmthera.2007.11.002
Citations Scopus - 63Web of Science - 53
Co-authors Philip Hansbro, Nicole Hansbro, Jay Horvat
2008 Wark P, 'Bronchitis (acute)', BMJ clinical evidence, 2008 (2008)

INTRODUCTION: Acute bronchitis, with transient inflammation of the trachea and major bronchi, affects over 40/1000 adults a year in the UK. The causes are usually considered to be... [more]

INTRODUCTION: Acute bronchitis, with transient inflammation of the trachea and major bronchi, affects over 40/1000 adults a year in the UK. The causes are usually considered to be infective, but only around half of people have identifiable pathogens. The role of smoking or of environmental tobacco smoke inhalation in predisposing to acute bronchitis is unclear. A third of people may have longer-term symptoms or recurrence.METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical question: What are the effects of treatments for acute bronchitis in people without chronic respiratory disease? We searched: Medline, Embase, The Cochrane Library, and other important databases up to September 2007 (BMJ Clinical Evidence reviews are updated periodically; please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).RESULTS: We found 19 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: antibiotics (amoxicillin [with or without clavulanic acid], cephalosporins, or macrolides), antihistamines, antitussives, beta(2) agonists (inhaled or oral), cephalosporins, expectorants, and analgesics.

2007 Weckmann M, Collison A, Simpson JL, Kopp MV, Wark PA, Smyth MJ, et al., 'Critical link between TRAIL and CCL20 for the activation of T(H)2 cells and the expression of allergic airway disease', Nature Medicine, 13 1308-1315 (2007) [C1]
DOI 10.1038/nm1660
Citations Scopus - 70Web of Science - 67
Co-authors Nicole Hansbro, Peter Gibson, Jodie Simpson, Paul Foster, Adam Collison, Joerg Mattes
2007 Wark PA, Bucchieri F, Johnston SL, Gibson PG, Hamilton L, Mimica J, et al., 'IFN-gamma-induced protein 10 is a novel biomarker of rhinovirus-induced asthma exacerbations', Journal of Allergy and Clinical Immunology, 120 586-593 (2007) [C1]
DOI 10.1016/j.jaci.2007.04.046
Citations Scopus - 90Web of Science - 84
Co-authors Peter Gibson, Joanna Latter, John Attia
2006 Wark PA, Gibson PG, 'Asthma exacerbations 3: Pathogenesis', Thorax, 61 909-915 (2006) [C1]
DOI 10.1136/thx.2005.045187
Citations Scopus - 65Web of Science - 55
Co-authors Peter Gibson
2006 Wark PA, 'Safety concerns with salmeterool', Australian Prescriber, 29 118-119 (2006) [C3]
2006 Wark P, 'Bronchitis (acute).', Clinical evidence, 1996-2005 (2006)
Citations Scopus - 1
2006 Contoli M, Message SD, Laza-Stanca V, Edwards MR, Wark PA, Bartlett N, et al., 'Role of eficient type III interferon-lambda production in asthma exacerbations', Nature Medicine, 12 1023-1026 (2006) [C1]
DOI 10.1038/nm1462
Citations Scopus - 541Web of Science - 485
Co-authors Nathan Bartlett
2005 Wark PAB, McDonald V, Jones AP, 'Nebulised hypertonic saline for cystic fibrosis', COCHRANE DATABASE OF SYSTEMATIC REVIEWS, (2005)
DOI 10.1002/14651858.CD001506.pub2
Citations Scopus - 7Web of Science - 1
Co-authors Vanessa Mcdonald
2005 Wood LG, Garg ML, Simpson JL, Mori TA, Croft KD, Wark PA, Gibson PG, 'Induced sputum 8-isoprostane concentrations in inflammatory airway diseases', American Journal of Respiratory and Critical Care Medicine, 171 426-430 (2005) [C1]
DOI 10.1164/rccm.200408-1010OC
Citations Scopus - 64Web of Science - 56
Co-authors Manohar Garg, Jodie Simpson, Lisa Wood, Peter Gibson
2005 Wark P, 'Bronchitis (acute).', Clinical evidence, 1844-1852 (2005)
2005 Wark PA, Johnston S, Bucchieri F, Powell R, Puddicombe S, Laza-Stanca V, et al., 'Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus', Journal of Experimental Medicine, 201 937-947 (2005) [C1]
DOI 10.1084/jem.20041901
Citations Scopus - 631Web of Science - 551
2004 Wark PA, 'Pathogenesis of allergic bronchopulmonary aspergillosis and an evidence-based review of azoles in treatment', Respiratory Medicine, 98 915-923 (2004) [C1]
DOI 10.1016/j.rmed.2004.07.002
Citations Scopus - 32
2004 Wark PA, 'Bronchitis (acute)', American Family Physician, 70 557-558 (2004)
2004 Walter E, Gibbins N, Vandersteen A, Kinton L, Wark P, Jonas M, 'Hyperkalaemic ascending paralysis', Journal of the Royal Society of Medicine, 97 330-331 (2004)
DOI 10.1258/jrsm.97.7.330
Citations Scopus - 5
2004 Wark P, 'Bronchitis (acute).', Clinical evidence, 1923-1932 (2004)
2004 Wark PA, Gibson PG, Wilson AJ, 'Azoles for allergic bronchopulmonary aspergillosis associated with asthma.', Cochrane database of systematic reviews (Online), (2004)

BACKGROUND: Allergic bronchopulmonary aspergillosis is hypersensitivity to the fungus Aspergillus fumigatus that complicates patients with asthma and cystic fibrosis. The mainstay... [more]

BACKGROUND: Allergic bronchopulmonary aspergillosis is hypersensitivity to the fungus Aspergillus fumigatus that complicates patients with asthma and cystic fibrosis. The mainstay of treatment for allergic bronchopulmonary aspergillosis remains oral corticosteroids, though this does not completely prevent exacerbations and may not prevent the decline in lung function. OBJECTIVES: The purpose of this review was to determine the efficacy of azoles in the treatment of allergic bronchopulmonary aspergillosis. SEARCH STRATEGY: We searched the Cochrane Airways Group Asthma trials register using the terms: (allergic bronchopulmonary aspergillosis OR aspergillosis OR allergic pulmonary aspergillosis OR allergic fungal and disease OR allergic mycotic and disease) AND (azole OR triazole OR itraconazole OR ketoconazole). Date of last search January 2003. SELECTION CRITERIA: All controlled trials that assessed the effect of azole antifungal agents compared to placebo or other standard therapy for allergic bronchopulmonary aspergillosis were reviewed. Patients with cystic fibrosis were not included. DATA COLLECTION AND ANALYSIS: Two reviewers independently assessed trial quality and extracted data. Study authors were contacted for additional information. Adverse effects information was collected from the trials. MAIN RESULTS: Twelve trials were identified, but only three were prospective, randomised and controlled. A total of 94 participants were included. One demonstrated a reduction in immunological markers of disease activity and symptom scores using ketoconazole 400 mg daily for 12 months. There was no significant improvement in lung function. The other two examined the use of itraconazole for 16 weeks. In one there was a reduction in sputum eosinophils by 35% compared to 19% with placebo (p < 0.01). In the same trial, the number of exacerbations requiring oral corticosteroids was 0.4 per patient with itraconazole compared with 1.3 per patient with placebo (p < 0.03). Meta-analysis of data from both trials showed that itraconazole treated patients were more likely to have decline in serum IgE over 25% or more (Peto OR 3.30; 95% confidence intervals 1.30 to 8.15). REVIEWERS' CONCLUSIONS: Itraconazole modifies the immunologic activation associated with allergic bronchopulmonary aspergillosis and improves clinical outcome, at least over the period of 16 weeks. Adrenal suppression with inhaled corticosteroids and itraconazole is a potential concern.

Citations Scopus - 12
2004 Wark PA, 'Bronchitis (acute)', Clinical Evidence, 12 (2004) [C3]
2003 Simpson JL, Moric I, Wark PA, Johnston S, Gibson PG, 'Use of induced sputum for the diagnosis of influenza and infections in asthma: a comparison of diagnostic techniques', Journal of Clinical Virology, 339-346 (2003) [C1]
DOI 10.1016/S1386-6532(02)00084-7
Citations Scopus - 34Web of Science - 27
Co-authors Peter Gibson, Jodie Simpson
2003 Wark P, 'Drug treatment for chronic obstructive pulmonary disease', IDrugs, 6 874-879 (2003)

The aim of this article is to review therapeutic agents that are currently being developed for chronic obstructive pulmonary disease (COPD) and examine them in the context of how ... [more]

The aim of this article is to review therapeutic agents that are currently being developed for chronic obstructive pulmonary disease (COPD) and examine them in the context of how they may influence disease progression. Developing disease-modifying agents for COPD has been identified as a priority by the World Health Organization, and the migration of inflammatory cells, the inflammatory response, antiproteases and mucociliary clearance have all been identified as viable targets for treating the disease. © Current Drugs.

2003 Wark P, 'Acute bronchitis.', Clinical evidence, 1716-1723 (2003)
2003 Wark PA, McDonald V, 'Nebulised hypertonic saline for cystic fibrosis.', Cochrane database of systematic reviews (Online), (2003)

BACKGROUND: The lung disease in cystic fibrosis is characterised by impaired mucociliary clearance. Hypertonic saline (HS) has been shown to enhance mucociliary clearance in-vitro... [more]

BACKGROUND: The lung disease in cystic fibrosis is characterised by impaired mucociliary clearance. Hypertonic saline (HS) has been shown to enhance mucociliary clearance in-vitro and this may act to lessen the destructive inflammatory process in the airways. OBJECTIVES: To investigate the effects of treatment with nebulised hypertonic saline on people with CF compared to placebo and or other treatments that enhance mucociliary clearance. SEARCH STRATEGY: 'We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group trials register which comprises references identified from comprehensive electronic database searches, handsearching relevant journals and handsearching abstract books of conference proceedings. Date of the most recent search of the Group's register: October 2001. SELECTION CRITERIA: All controlled trials (any language) assessing the effect of hypertonic saline compared to placebo or other mucolytic therapy, for any duration or dose regimen in people with cystic fibrosis of any age or severity. DATA COLLECTION AND ANALYSIS: All identified trials were independently reviewed by both reviewers & all data collected. Trial quality was assessed along with allocation concealment. MAIN RESULTS: Fourteen controlled trials were identified. Nine trials met the inclusion criteria; these involved 235 participants with an age range of 6 to 46 years. Two short-term trials of immediate effect on mucociliary clearance demonstrated that HS increased isotope clearance compared to control. Lung function as measured by improvement in Forced Expiratory Volume at one second (FEV1 l/min) was observed in four trials. When 3% to 7% saline was used in a volume of 10mls twice a day, in comparison to placebo, HS led to a significant increase in FEV1, WMD 12.20 (95%CI 4.30 to 20.10). In comparison to deoxyribonuclease (DNase) two trials used a similar concentration and volume of HS. Over a three week period the groups showed a similar increase in FEV1, WMD -1.60 (95%CI -11.16 to 7.96). However after 12 weeks treatment in participants with moderate to severe lung disease compared to DNase, HS 5mls twice a day showed less benefit to FEV1, WMD -13.00 (95%CI -22.46 to -3.54). No serious adverse events were noted. REVIEWER'S CONCLUSIONS: Nebulised hypertonic saline improves mucociliary clearance in short term clinical trials and appears to increase lung function compared to control. In comparison to DNase it may be less effective at improving lung function, after three months. At this stage there is insufficient evidence to support the use of hypertonic saline as routine treatment for people with cystic fibrosis.

2003 Wark PA, Gibson PG, Wilson AJ, 'Azoles for allergic bronchopulmonary aspergillosis associated with asthma.', Cochrane database of systematic reviews (Online), (2003)

BACKGROUND: Allergic bronchopulmonary aspergillosis is hypersensitivity to the fungus Aspergillus fumigatus that complicates patients with asthma and cystic fibrosis. The mainstay... [more]

BACKGROUND: Allergic bronchopulmonary aspergillosis is hypersensitivity to the fungus Aspergillus fumigatus that complicates patients with asthma and cystic fibrosis. The mainstay of treatment for allergic bronchopulmonary aspergillosis remains oral corticosteroids, though this does not completely prevent exacerbations and may not prevent the decline in lung function. OBJECTIVES: The purpose of this review was to determine the efficacy of azoles in the treatment of allergic bronchopulmonary aspergillosis. SEARCH STRATEGY: We searched the Cochrane Airways Group Asthma trials register using the terms: (allergic bronchopulmonary aspergillosis OR aspergillosis OR allergic pulmonary aspergillosis OR allergic fungal and disease OR allergic mycotic and disease) AND (azole OR triazole OR itraconazole OR ketoconazole). Date of last search January 2003. SELECTION CRITERIA: All controlled trials that assessed the effect of azole antifungal agents compared to placebo or other standard therapy for allergic bronchopulmonary aspergillosis were reviewed. Patients with cystic fibrosis were not included. DATA COLLECTION AND ANALYSIS: Two reviewers independently assessed trial quality and extracted data. Study authors were contacted for additional information. Adverse effects information was collected from the trials. MAIN RESULTS: Twelve trials were identified, but only three were prospective, randomised and controlled. A total of 94 participants were included. One demonstrated a reduction in immunological markers of disease activity and symptom scores using ketoconazole 400 mg daily for 12 months. There was no significant improvement in lung function. The other two examined the use of itraconazole for 16 weeks. In one there was a reduction in sputum eosinophils by 35% compared to 19% with placebo (p < 0.01). In the same trial, the number of exacerbations requiring oral corticosteroids was 0.4 per patient with itraconazole compared with 1.3 per patient with placebo (p < 0.03). Meta-analysis of data from both trials showed that itraconazole treated patients were more likely to have decline in serum IgE over 25% or more (Peto OR 3.30; 95% confidence intervals 1.30 to 8.15). REVIEWER'S CONCLUSIONS: Itraconazole modifies the immunologic activation associated with allergic bronchopulmonary aspergillosis and improves clinical outcome, at least over the period of 16 weeks. Adrenal suppression with inhaled corticosteroids and itraconazole is a potential concern.

2003 Wark PA, Hensley MJ, Saltos N, Boyle MJ, Toneguzzi R, Simpson JL, et al., 'Anti-inflammatory effect of itraconazole in stable allergic bronchopulmonary aspergillosis: A randomized controlled trial', The Journal of Allergy and Clinical Immunology, 111 952-957 (2003) [C1]
DOI 10.1067/mai.2003.1388
Citations Scopus - 160Web of Science - 122
Co-authors Michael Hensley, Jodie Simpson, Peter Gibson
2003 Gibson PG, Wark PA, Simpson JL, Meldrum CJ, Meldrum S, Saltos N, Boyle MJ, 'Induced sputum IL-8 gene expression, neutrophil influx and MMP-9 in allergic bronchopulmonary aspergillosis', European Respiratory Journal, 21 582-588 (2003) [C1]
DOI 10.1183/09031936.03.00001803
Citations Scopus - 40Web of Science - 30
Co-authors Jodie Simpson, Peter Gibson
2003 Wark PAB, Gibson PG, 'Clinical Usefulness of Inflammatory Markers in Asthma', American Journal of Respiratory & Critical Care Medicine, 2 11-19 (2003) [C1]
Citations Scopus - 23
Co-authors Peter Gibson
2002 Wark PA, Johnston S, Simpson JL, Hensley MJ, Gibson PG, 'Chlamydia pneumoniae immunoglobulin A reactivation and airway inflammation in acute asthma', The European Respiratory Journal, 20 834-840 (2002) [C1]
Citations Scopus - 52Web of Science - 44
Co-authors Peter Gibson, Jodie Simpson, Michael Hensley
2002 Wark PA, Johnston S, Moric I, Simpson JL, Hensley MJ, Gibson PG, 'Neutrophil degranulation and cell lysis is associated with clinical severity in virus-induced asthma', The European Respiratory Journal, 19 68-75 (2002) [C1]
Citations Scopus - 224Web of Science - 194
Co-authors Jodie Simpson, Peter Gibson, Michael Hensley
2002 Gibson PG, Grootendor D, Henry R, Pin I, Rytila P, Wark P, et al., 'Sputum induction in children', European Respiratory Journal, 37 44s-46s (2002) [C3]
Citations Scopus - 27Web of Science - 4
Co-authors Peter Gibson
2002 Wark PA, Simpson JL, Hensley MJ, Gibson PG, 'Airway inflammation in thunderstorm asthma', Clinical and Experimental Allergy, 32 1750-1756 (2002) [C1]
Citations Scopus - 27Web of Science - 21
Co-authors Peter Gibson, Jodie Simpson, Michael Hensley
2002 Wark PAB, 'DX-890 Dyax', IDrugs, 5 586-589 (2002)

Dyax (formerly Protein Engineering Corp) and Debiopharm are developing DX-890, an inhibitor of human ncutrophil elastase (HNE),for the potential treatment of pulmonary diseases su... [more]

Dyax (formerly Protein Engineering Corp) and Debiopharm are developing DX-890, an inhibitor of human ncutrophil elastase (HNE),for the potential treatment of pulmonary diseases such as cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD). In December 1999, Debiopharm initiated phase I trials with an aerosol formulation of DX-890; studies were completed by October 2000. By August 2000, DX-890 was in phase II evaluation for the potential treatment of CF, and in May 2002, Dyax planned to initiate a further study, in children with CF, within the year. By June 2002, phase II trials in CF were ongoing in France and Spain, with results expected soon after this date. In September 2000, JP Morgan predicted a 2005 launch for this drug, with estimated sales in that year of US $23 million rising to US $63 million in 2007. © PharmaPress Ltd.

Citations Scopus - 10
2002 Simpson JL, Gibson PG, Wark PA, 'Optimization of sputum-processing methods for the measurement of interleukin-5: Effects of protease inhibition', Respirology, 7 111-116 (2002) [C1]
Citations Scopus - 8Web of Science - 10
Co-authors Jodie Simpson, Peter Gibson
2001 Wark PA, Simpson J, Hensley MJ, Gibson PG, 'Safety of sputum induction with isotonic saline in adults with acute severe asthma', Clinical and Experimental Allergy, 31 1745-1753 (2001) [C1]
Citations Scopus - 29Web of Science - 24
Co-authors Peter Gibson, Michael Hensley, Jodie Simpson
2001 Gibson PG, Simpson J, Chalmers AC, Toneguzzi R, Wark PA, Wilson AJ, Hensley MJ, 'Airway Eosinophilia is associated with Wheeze but is uncommon in Children with Persistent Cough and Frequent Chest Colds', American Journal of Respiratory and Critical Care Medicine, 164 977-981 (2001) [C1]
Citations Scopus - 45Web of Science - 36
Co-authors Jodie Simpson, Amanda Wilson, Anita Chalmers, Peter Gibson, Michael Hensley
2001 Wark PA, 'Sputum lactate dehydrogenase, a marker of cell necrosis, is elevated in acute asthma', Respirology, 6 (2001)

Rationale: The role of neutrophils in airway inflammation in acute asthma is unclear. Lactate dehydrogenase (LDH) is a marker of cell necrosis. The aim of this study was to determ... [more]

Rationale: The role of neutrophils in airway inflammation in acute asthma is unclear. Lactate dehydrogenase (LDH) is a marker of cell necrosis. The aim of this study was to determine if levels of LDH were elevated in acute asthma and to determine how this related to airway inflammation and the clinical severity of acute asthma. Methods: Subjects with acute asthma had spirometry and sputum induction. Infection was determined using sputum PCR for common respiratory viruses. Sputum supernatant LDH activity was measured using the enzymatic rate method with isoenzyme pattern determined by gel electrophoresis. Results: We recruited 37 subjects with acute severe asthma: 12 had infection with respiratory syncytial virus (RSV), 9 with influenza, 6 picornaviruses, 10 non-infective exacerbations. There were 8 healthy controls. Sputum LDH was highest in those with RSV (653.1 lU/mL), influenza infection (549.5 lU/raL) and picornaviruses (501.2 lU/mL) compared to those with no infection (182 lU/mL), while all those with acute asthma were higher than the controls (25 lU/mL, p 0.01). LDH-5 was the main isoenzyme present suggesting neutrophil lysis with elevated LDH-5. Sputum LDH was associated with elevated sputum neutrophils (r = 0.8), a lower FEV| (r = -0.5), more severe acute symptoms (r = 0.6) and a longer length of hospital stay (r = 0.4). Conclusion: Sputum LDH is elevated in acute asthma with viral infection. Cell necrosis in acute asthma may potentiate neutrophilic airway inflammation and more severe clinical disease.

2001 Wark P, Wilson AJ, Gibson PG, 'Azoles for allergic bronchopulmonary aspergillosis', Praxis, 90 1780 (2001)
2001 Wark PA, Gibson PG, Johnston S, 'Exacerbations of asthma: addressing the triggers and treatments', Monaldi Archives for Chest Disease, 56 429-435 (2001) [C1]
Citations Scopus - 10
Co-authors Peter Gibson
2001 Wark PA, Gibson PG, 'Allergic bronchopulmonary aspergillosis: New concepts of pathogenesis and treatment', Respirology, 6 1-7 (2001) [C2]
Citations Scopus - 53
Co-authors Peter Gibson
2001 Wark P, Wilson AW, Gibson PG, 'Azoles for allergic bronchopulmonary aspergillosis associated with asthma.', Cochrane database of systematic reviews (Online), (2001)

BACKGROUND: Allergic Broncho-pulmonary Aspergillosis is hypersensitivity to the fungus Aspergillus fumigatus that complicates patients with asthma and cystic fibrosis. The mainsta... [more]

BACKGROUND: Allergic Broncho-pulmonary Aspergillosis is hypersensitivity to the fungus Aspergillus fumigatus that complicates patients with asthma and cystic fibrosis. The mainstay of treatment for ABPA remains oral corticosteroids, though this does not completely prevent exacerbations and may not prevent the decline in lung function. OBJECTIVES: The purpose of this review was to determine the efficacy of azoles in the treatment of Allergic Broncho-pulmonary Aspergillosis. SEARCH STRATEGY: The Cochrane Airways Group Asthma register was searched using the terms: (allergic bronchopulmonary aspergillosis OR aspergillosis OR allergic pulmonary aspergillosis OR allergic fungal and disease OR allergic mycotic and disease) AND (azole OR triazole OR itraconazole OR ketoconazole). SELECTION CRITERIA: All controlled trials that assessed the effect of azole antifungal agents compared to placebo or other standard therapy for ABPA were reviewed. Patients with cystic fibrosis were not included. DATA COLLECTION AND ANALYSIS: All identified trials were independently reviewed by both reviewers & all data collected. Trial quality was scored by the Cochrane assessment of allocation concealment & the Jadad scale of methodological quality. MAIN RESULTS: Twelve trials were identified, but only three were prospective, randomised and controlled. One demonstrated a reduction in immunological markers of disease activity and symptom scores using ketoconazole 400 mg daily for 12 month. There was no significant improvement in lung function. The other two examined the use of itraconazole for 16 weeks. In one there was a reduction in sputum eosinophils by 35% compared to 19% with placebo (p<0.01). In the same trial, the number of exacerbations requiring oral corticosteroids was 0.4 per patient with itraconazole compared with 1.3 per patient with placebo (p<0.03). Meta analysis of data from both trials showed that itraconazole treated patients were more likely to have decline in serum IgE over 25% or more (Odds Ratio 3.3; 95% confidence intervals 1.3, 8.2). REVIEWER'S CONCLUSIONS: Itraconazole modifies the immunologic activation associated with ABPA and improves clinical outcome in ABPA at least over the period of 16 weeks.

Citations Scopus - 21
Co-authors Peter Gibson
2000 Wark PA, Saltos N, Simpson J, Slater S, Hensley MJ, Gibson PG, 'Induced sputum easinophils and neutrophils and bronchiectasis severity in allergic bronchopulmonary aspergillosis', European Respiratory Journal, 16 1095-1101 (2000) [C1]
Citations Scopus - 56Web of Science - 43
Co-authors Peter Gibson, Michael Hensley, Jodie Simpson
2000 Wark PA, Gibson PG, Fakes K, 'Induced sputum eosinophils in the assessment of asthma and chronic cough*', Respirology, 5 51-57 (2000) [C1]
Citations Scopus - 19
Co-authors Peter Gibson
2000 Wark PA, Wilson A, Gibson PG, 'Azoles for allergic bronchopulmonary aspergillosis', The Cochrane Library, 1-9 (2000) [C1]
Co-authors Peter Gibson
2000 Wark PA, McDonald V, 'Nebulised hypertonic saline for cystic fibrosis.', Cochrane database of systematic reviews (Online : Update Software), (2000)

BACKGROUND: The lung disease in cystic fibrosis is characterised by impaired mucociliary clearance, recurrent bronchial infection and airway inflammation. Hypertonic saline has be... [more]

BACKGROUND: The lung disease in cystic fibrosis is characterised by impaired mucociliary clearance, recurrent bronchial infection and airway inflammation. Hypertonic saline has been shown to enhance mucociliary clearance in-vitro and this may act to lessen the destructive inflammatory process in the airways. OBJECTIVES: To determine if nebulised hypertonic saline treatment improved lung function, exercise tolerance, quality of life and decreased the incidence of exacerbations of respiratory infections in patients with cystic fibrosis. SEARCH STRATEGY: Studies were identified from the Cochrane Cystic Fibrosis and Genetic Disorders Group trials register. Titles and abstracts were reviewed to identify all controlled trials. Review articles and bibliographies identified from this process were surveyed for additional citations & RCTs. Identification of unpublished work was obtained from abstract books from the three major Cystic Fibrosis conferences (International Cystic Fibrosis Conference, The European Cystic Fibrosis Conference and the North American Cystic Fibrosis Conference). Trial authors were contacted for additional information when only abstracts were available to review. Date of the most recent search of the Group's specialised register: November 1999. SELECTION CRITERIA: All controlled trials that assessed the effect of hypertonic saline compared to placebo or other mucolytic therapy, for any duration or dose regimen in subjects with cystic fibrosis of any age or severity were reviewed. Studies in languages other than English were included. DATA COLLECTION AND ANALYSIS: All identified trials were independently reviewed by both reviewers & all data collected. Trial quality was scored by the Cochrane assessment of allocation concealment & the Jadad scale of methodological quality. MAIN RESULTS: Twelve controlled trials of hypertonic saline were identified. Seven trials met the inclusion criteria; these involved 143 subjects with an age range of 6 to 46 years. Of these, six were published studies and one in abstract form. The durations of the trials were limited to immediate effects on mucociliary clearance to a maximum of three weeks. In two studies, involving thirty five subjects, a score for the feeling of cleared chest was made using visual analogue scales. This analysis showed a weighted mean difference of -0.98 (95% confidence Interval -1.6, -0.34), favouring hypertonic saline over isotonic saline. In two trials with 22 subjects hypertonic saline improved mucociliary clearance as measured by isotope clearance from the lungs in 90 minutes demonstrating a weighted mean difference of -11.3 (95% confidence Interval -18.6, -4.0), and as area under the clearance time curve; weighted mean difference of -212 (95%CI -272, -152), also favouring hypertonic saline over isotonic saline. Lung function as measured by improvement in FEV1 was observed in one study of 27 subjects. The percentage increase in FEV1 at two weeks increased by a mean 15.0% with hypertonic saline and 2.8% with isotonic saline (p=0.004). Adverse events were adequately described in only one trial and none were serious. REVIEWER'S CONCLUSIONS: Nebulised hypertonic saline improves mucociliary clearance immediately after administration which may have a longer term beneficial effect in cystic fibrosis. The maximum time data were recorded for was only three weeks. Most of the patients had mild to moderate lung disease and the effect on severe lung disease remains unclear. Further studies of hypertonic saline should be carried out to determine the effect on pulmonary function tests, quality of life, frequency of exacerbations of respiratory disease and efficacy comparisons with nebulised deoxyribonuclease, with larger numbers and for longer duration. At this stage there is insufficient evidence to support the use of hypertonic saline in routine treatment for patients with cystic fibrosis.

Citations Scopus - 1
Co-authors Vanessa Mcdonald
2000 Wark PA, McDonald V, 'Nebulised hypertonic saline for cystic fibrosis.', Cochrane database of systematic reviews (Online), (2000)

BACKGROUND: The lung disease in cystic fibrosis is characterised by impaired mucociliary clearance, recurrent bronchial infection and airway inflammation. Hypertonic saline has be... [more]

BACKGROUND: The lung disease in cystic fibrosis is characterised by impaired mucociliary clearance, recurrent bronchial infection and airway inflammation. Hypertonic saline has been shown to enhance mucociliary clearance in-vitro and this may act to lessen the destructive inflammatory process in the airways. OBJECTIVES: To determine if nebulised hypertonic saline treatment improved lung function, exercise tolerance, quality of life and decreased the incidence of exacerbations of respiratory infections in patients with cystic fibrosis. SEARCH STRATEGY: Studies were identified from the Cochrane Cystic Fibrosis and Genetic Disorders Group trials register. Titles and abstracts were reviewed to identify all controlled trials. Review articles and bibliographies identified from this process were surveyed for additional citations & RCTs. Identification of unpublished work was obtained from abstract books from the three major Cystic Fibrosis conferences (International Cystic Fibrosis Conference, The European Cystic Fibrosis Conference and the North American Cystic Fibrosis Conference). Trial authors were contacted for additional information when only abstracts were available to review. Date of the most recent search of the Group's specialised register: November 1999. SELECTION CRITERIA: All controlled trials that assessed the effect of hypertonic saline compared to placebo or other mucolytic therapy, for any duration or dose regimen in subjects with cystic fibrosis of any age or severity were reviewed. Studies in languages other than English were included. DATA COLLECTION AND ANALYSIS: All identified trials were independently reviewed by both reviewers & all data collected. Trial quality was scored by the Cochrane assessment of allocation concealment & the Jadad scale of methodological quality. MAIN RESULTS: Twelve controlled trials of hypertonic saline were identified. Seven trials met the inclusion criteria; these involved 143 subjects with an age range of 6 to 46 years. Of these, six were published studies and one in abstract form. The durations of the trials were limited to immediate effects on mucociliary clearance to a maximum of three weeks. In two studies, involving thirty five subjects, a score for the feeling of cleared chest was made using visual analogue scales. This analysis showed a weighted mean difference of -0.98 (95% confidence Interval -1.6, -0.34), favouring hypertonic saline over isotonic saline. In two trials with 22 subjects hypertonic saline improved mucociliary clearance as measured by isotope clearance from the lungs in 90 minutes demonstrating a weighted mean difference of -11.3 (95% confidence Interval -18.6, -4.0), and as area under the clearance time curve; weighted mean difference of -212 (95%CI -272, -152), also favouring hypertonic saline over isotonic saline. Lung function as measured by improvement in FEV1 was observed in one study of 27 subjects. The percentage increase in FEV1 at two weeks increased by a mean 15.0% with hypertonic saline and 2.8% with isotonic saline (p=0.004). Adverse events were adequately described in only one trial and none were serious. REVIEWER'S CONCLUSIONS: Nebulised hypertonic saline improves mucociliary clearance immediately after administration which may have a longer term beneficial effect in cystic fibrosis. The maximum time data were recorded for was only three weeks. Most of the patients had mild to moderate lung disease and the effect on severe lung disease remains unclear. Further studies of hypertonic saline should be carried out to determine the effect on pulmonary function tests, quality of life, frequency of exacerbations of respiratory disease and efficacy comparisons with nebulised deoxyribonuclease, with larger numbers and for longer duration. At this stage there is insufficient evidence to support the use of hypertonic saline in routine treatment for patients with cystic fibrosis.

Citations Scopus - 6
Co-authors Vanessa Mcdonald
2000 Wark P, Wilson AW, Gibson PG, 'Azoles for allergic bronchopulmonary aspergillosis.', Cochrane database of systematic reviews (Online), (2000)

BACKGROUND: Allergic Broncho-pulmonary Aspergillosis (ABPA) is hypersensitivity to the fungus Aspergillus Fumigatus that complicates patients with asthma and cystic fibrosis. The ... [more]

BACKGROUND: Allergic Broncho-pulmonary Aspergillosis (ABPA) is hypersensitivity to the fungus Aspergillus Fumigatus that complicates patients with asthma and cystic fibrosis. The condition usually results in an increase in symptoms, a greater reliance on corticosteroids to control the disease process and may lead to a progressive decline in lung function. The mainstay of treatment for ABPA remains oral corticosteroids, though this does not completely prevent exacerbations and may not prevent the decline in lung function. OBJECTIVES: The purpose of this review is to determine the efficacy of azoles in the treatment of ABPA SEARCH STRATEGY: An initial search was carried out using the Cochrane Airways Group Asthma RCT register. The register was searched using the following terms: (asthma or wheeze) and (allergic bronchopulmonary aspergillosis or aspergillosis or allergic pulmonary aspergillosis or allergic fungal and disease or allergic mycotic and disease) and (azole or triazole or itraconazole or ketoconazole). SELECTION CRITERIA: All controlled trials that assessed the effect of azole antifungal agents compared to placebo or other standard, for any duration or dose regimen in subjects with ABPA of any age or severity were reviewed. Studies in languages other than English were included. DATA COLLECTION AND ANALYSIS: All identified trials were independently reviewed by both reviewers & all data collected. Trial quality was scored by the Cochrane assessment of allocation concealment & the Jadad scale of methodological quality. MAIN RESULTS: A total of 11 trials were identified concerning the use of azoles in ABPA. Only two prospective controlled trials were identified. The first trial examined the use of Ketoconazole 400 mg daily for 12 months and demonstrated a reduction in immunological markers of disease activity and symptom scores, there was no significant improvement in lung function. The other trial examined the use of itraconazole for 16 weeks. This demonstrated a reduction in corticosteroid usage, an improvement in immunological markers, an improvement in pulmonary function and exercise tolerance. This study was only available as an abstract and limited details were available. REVIEWER'S CONCLUSIONS: There is insufficient information available to recommend the use of azole anti-fungal agents in the routine treatment of patients with ABPA.

Co-authors Peter Gibson
1999 Wark PAB, Fakes K, Gibson PG, 'Induced sputum eosinophils in the assessment of asthma and chronic cough.', AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 159 A850-A850 (1999)
1999 Wark P, Simpson J, Fakes K, Burgess H, Timmins N, Hensley M, Gibson PG, 'Airway inflammation in allergic bronchopulmonary aspergillosis', Respirology, 4 (1999)

Allergic bronchopulmonary aspergillosis (ABPA) is a serious complication of asthma. In uncomplicated asthma airway inflammation(ai) is characterised by sputum eosinophilia without... [more]

Allergic bronchopulmonary aspergillosis (ABPA) is a serious complication of asthma. In uncomplicated asthma airway inflammation(ai) is characterised by sputum eosinophilia without an increase in the total cell count (TCC). In bronchiectasis the intensity of ai increased and there is a neutrophil infiltrate. Airway inflammation in ABPA is not well defined. This study tested the hypothesis that ai in ABPA would be of increased intensity with a mixed eosinophil/neutrophil pattern. Methods: In subjects with asthma, ABPA was assessed by 5 criteria; 1. positive allergy skin test to Aspergillus Fumigatus (Af); 2. raised specific serum IgE to Af; 3. positive precipitating antibodies to Af; 4. total IgE > 10001U/ml and 5. bronchiectasis (CT scan). Subjects were classified as definite ABPA (n=13) with criteria 1, 2, 3 and either 4 or 5; or as probable ABPA (n=18) with 1 and 2 and either 3, 4 or 5 (n=13). These groups were combined for analysis. Af sensitised subjects (n=19 with positive skin testing alone), were compared to a matched group with asthma (negative to Af on skin test) (n=15) and healthy controls (n=8). Spirometry, saline challenge and sputum induction were performed, with results reported as medians and interquartile ranges. Results: Patients with ABPA had an increased TCC (4.6, 0.9-29.6) compared to: Af sensitised (3.6, 1.4-7.4), asthma (1.5, 0.8-3.2), and controls (1.35, 1.3-1.4) (p<0.05). Those with ABPA had increased sputum eosinophils (3.8, 0.3-16.3), compared to: Af sensitised (1.4, 0.1-6), asthma (1.6, 0.01-3), and controls (0.3, 0.3-0.31 ) (p=0.001). Those with ABPA had increased levels of eosinophil cationic protein(ng/ml) (5471, 311-42485) compared to: Af sensitised (1432, 338-6902), asthma (244, 78-857), and controls (110, 99-121 ) (p<0.001). Neutrophil counts were similar in all groups. Myeloperoxidase was similar in ABPA (232, 66-454) and asthma (177, 57-318) (p=0.3) but greater than in healthy controls (76, 76-89) Conclusion: Airway inflammation in ABPA is of increased intensity compared to that of chronic asthma. Unlike bronchiectasis, the cellular infiltrate is predominantly eosinophilic. The eosinophils demonstrate increased activation.

Co-authors Peter Gibson
1999 Wark P, McDonald V, 'The effectiveness of nebulised hypertonic saline on lung function, exercise tolerance and quality of life in cystic fibrosis', Respirology, 4 (1999)

Thick tenacious secretions that are difficult to expectorate and recurrent infection that leads to progressive end stage fibrotic disease typify lung disease in cystic fibrosis (C... [more]

Thick tenacious secretions that are difficult to expectorate and recurrent infection that leads to progressive end stage fibrotic disease typify lung disease in cystic fibrosis (CF). Mucolytic treatment can improve expectoration of sputum and lung function in CF. Our aim was to examine the efficacy of hypertonic saline (HS) in CF as an alternative or supplementary treatment. Methods: A meta-analysis of controlled trials was done. A search was carried out via the Cochrane Cystic Fibrosis Group specialist trials register. The titles and abstracts were reviewed to identify all potential controlled trials, articles were surveyed for additional citations. Identification of unpublished work was obtained from abstract books from (The International CF Conference, The European CF Conference and the North American CF Conference). All controlled trials that assessed the efficacy of Hypertonic Saline in subjects with cystic fibrosis were reviewed. The reviewers independently reviewed all trials. Data was analysed and compared using Revman. Results: A total of ten controlled trials were identified. Adequate data was available for analysis from seven of the studies, n = 166, age range (7-36years). Two studies showed that hypertonic saline (HS) improved lung function at two weeks by increasing the percentage change in FEV1. This showed a weighted mean difference (WMD) of +12.2 (95%CI +13.860, +10.540), favouring HS over isotonic saline (IS). An immediate effect on mucociliary clearance as measured by radioisotope was assessed in two trials. Analysis of isotope clearance at 90 mins found a WMD of +11.28 (95%CI +18.562, +3.998), favouring HS over IS. Measuring clearance as area under the curve showed a WMD of +212.059 (95%CI +271.641, +152.477), favouring HS over IS. Nebulised hypertonic saline appears to have a beneficial effect in cystic fibrosis, improving muco-ciliary clearance immediately after administration and lung function after two weeks of administration in combination with chest physiotherapy. Comparative data was not available to assess outcomes such as improvement in objective exercise testing, effect on symptom scores, quality of life measures or long term efficacy.

Co-authors Vanessa Mcdonald
1998 Wark P, Goldberg H, Ferson M, McKenzie D, Lau E, Rivas K, 'Mycobacterial lymphadenitis in eastern Sydney', AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, 28 453-458 (1998)
DOI 10.1111/j.1445-5994.1998.tb02080.x
Citations Scopus - 14Web of Science - 9
Show 116 more journal articles

Review (3 outputs)

Year Citation Altmetrics Link
2016 Grainge CL, Maltby S, Gibson PG, Wark PA, McDonald VM, 'Targeted therapeutics for severe refractory asthma: monoclonal antibodies.', Expert Rev Clin Pharmacol (2016)
DOI 10.1586/17512433.2016.1172208
Co-authors Peter Gibson, Christopher Grainge, Steven Maltby, Vanessa Mcdonald
2016 Wark PA, Hew M, Maltby S, McDonald VM, Gibson PG, 'Diagnosis and investigation in the severe asthma clinic.', Expert Rev Respir Med (2016)
DOI 10.1586/17476348.2016.1165096
Co-authors Vanessa Mcdonald, Peter Gibson, Steven Maltby
2004 Wark PA, Gibson PG, Wilson AJ, 'Azoles for Allergic Bronchopulmonary Aspergillosis Associated With Asthma', Cochrane Database of Systematic Reviews (2004) [D1]
DOI 10.1002/14651858.CD001108
Citations Scopus - 1
Co-authors Amanda Wilson, Peter Gibson

Conference (100 outputs)

Year Citation Altmetrics Link
2016 Negewo N, Mcdonald V, Baines K, Wark P, Simpson J, Jones P, Gibson P, 'BLOOD EOSINOPHILS AS A SURROGATE MARKER FOR SPUTUM EOSINOPHILIA IN STABLE COPD', RESPIROLOGY (2016)
Co-authors Peter Gibson, Vanessa Mcdonald, Jodie Simpson
2016 Jones B, Harrison C, Waters D, Dua K, Starkey M, Jarnicki A, et al., 'BROMODOMAIN INHIBITORS REVERSE THE DISEASE FEATURES IN EXPERIMENTAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE', RESPIROLOGY (2016)
Co-authors Philip Hansbro, Darryl Knight
2016 Moheimani F, Koops J, Williams T, Ried A, Wark P, Knight D, 'MICRORNAS EXPRESSION ABNORMALITIES IN ASTHMATIC EPITHELIAL CELLS', RESPIROLOGY (2016)
Co-authors Fatemeh Moheimani, Darryl Knight
2016 Gibson P, Reddel H, Jenkins C, Marks G, Upham J, Gillman A, et al., 'EFFECTIVENESS AND RESPONSE PREDICTORS OF OMALIZUMAB IN A SEVERE ALLERGIC ASTHMA POPULATION WITH A HIGH PREVALENCE OF COMORBIDITIES: THE AUSTRALIAN XOLAIR REGISTRY', RESPIROLOGY (2016)
Co-authors Vanessa Mcdonald, Peter Gibson
2016 Harvey E, Gibson P, Bardin P, Peters M, Reynolds P, Upham J, et al., 'CHARACTERISATION OF SEVERE ASTHMA PHENOTYPES VIA A SEVERE ASTHMA REGISTRY: THE SEVERE ASTHMA WEB-BASED DATABASE', RESPIROLOGY (2016)
Co-authors Vanessa Mcdonald, Peter Gibson
2016 Harvey E, Gibson P, Bardin P, Peters M, Reynolds P, Upham J, et al., 'SEVERE ASTHMA IS ASSOCIATED WITH WORK PRODUCTIVITY LOSS, ACTIVITY IMPAIRMENT AND REDUCED QUALITY OF LIFE', RESPIROLOGY (2016)
Co-authors Vanessa Mcdonald, Peter Gibson
2015 Jones B, Jarnicki A, Smithers N, Knight D, Wark P, Adcock I, Hansbro P, 'EPIGENETIC CHANGES IN HATS AND HDACS DRIVE PATHOGENESIS THAT CAN BE REVERSED USING BET INHIBITORS IN EXPERIMENTAL COPD', RESPIROLOGY (2015) [E3]
Co-authors Philip Hansbro, Darryl Knight
2015 Wark P, Tolosa J, Parsons K, Hansbro P, Smith R, 'THE PLACENTAL PROTEIN SYNCYTIN-1 IMPAIRS ANTIVIRAL RESPONSES AND EXAGGERATES INFLAMMATORY RESPONSES TO INFLUENZA', RESPIROLOGY (2015) [E3]
Co-authors Philip Hansbro, Roger Smith
2015 Hsu A, Parsons K, Hansbro P, Wark P, 'ENHANCED PI3K ACTIVITY LEADS TO DECREASED INTERFERON-beta RESPONSE TO INFLUENZA INFECTION IN COPD', RESPIROLOGY (2015) [E3]
Co-authors Alan Hsu, Philip Hansbro
2015 Loo S, Hsu A, Hansbro P, Wark P, 'THE ROLE OF PI3 KINASE IN INFLUENZA H1N1 AND RHINOVIRUS VIRAL ENTRY INTO PRIMARY BRONCHIAL EPITHELIAL CELLS', RESPIROLOGY (2015) [E3]
Co-authors Alan Hsu, Philip Hansbro
2015 Wark P, Mcdonald V, Gibson P, 'A TREATMENT ALGORITHM ADJUSTING ORAL CORTICOSTEROID USING BLOOD EOSINOPHILS REDUCES EXACERBATIONS AND IMPROVES ASTHMA CONTROL, IN DIFFICULT ASTHMATICS', RESPIROLOGY (2015) [E3]
Co-authors Peter Gibson, Vanessa Mcdonald
2015 Steven A, Gibson P, Wark P, Mcdonald V, 'THE USE OF AZOLES IN AIRWAYS DISEASE: A RETROSPECTIVE AUDIT', RESPIROLOGY (2015) [E3]
Co-authors Peter Gibson, Vanessa Mcdonald
2015 Jones B, Jarnicki AG, Smithers N, Knight DA, Wark PA, Adcock IM, Hansbro PM, 'Epigenetic Changes In Hats And Hdacs Drive Pathogenesis That Can Be Reversed Using Bet Inhibitors In Experimental COPD', AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2015)
Co-authors Philip Hansbro
2015 McDonald V, Wark P, Baines K, Gibson P, 'A multidimensional assessment of severe asthma', American Journal of Respiratory and Critical Care Medicine (2015) [E3]
Co-authors Peter Gibson, Katherine Baines, Vanessa Mcdonald
2015 McDonald V, Wark P, Baines K, Gibson P, 'The multidimensional components of severe asthma', Respirology (2015) [E3]
Co-authors Vanessa Mcdonald, Peter Gibson, Katherine Baines
2015 Hew M, Gillman A, Wark P, Bowden J, Sutherland M, Gibson P, 'OMALIZUMAB TREATMENT IMPROVES CLINICAL OUTCOME IN SEVERE ALLERGIC ASTHMA PATIENTS ABOVE THE DOSING RANGE', INTERNAL MEDICINE JOURNAL (2015) [E3]
Co-authors Peter Gibson
2014 Hsu A, Parsons K, Fujita T, Hansbro P, Wark P, 'Critical role of PKR in antiviral stress granule and IFN-beta enhanceosome formation, and is impaired in chronic obstructive pulmonary disease', CYTOKINE (2014) [E3]
DOI 10.1016/j.cyto.2014.07.088
Co-authors Alan Hsu, Philip Hansbro
2014 Hsu A, Parsons K, Hansbro P, Wark P, 'Enhanced PI3K activity leads to decreased IFN-beta response to influenza infection in chronic obstructive pulmonary disease', CYTOKINE (2014) [E3]
DOI 10.1016/j.cyto.2014.07.089
Co-authors Philip Hansbro, Alan Hsu
2014 Starkey M, Hanish I, Dua K, Nair P, Haw T, Hsu A, et al., 'Interleukin-13 predisposes mice to more severe influenza infection by suppressing interferon responses and activating microRNA-21/PI3K', CYTOKINE (2014) [E3]
DOI 10.1016/j.cyto2014.07.182
Co-authors Alan Hsu, Jay Horvat, Paul Foster, Darryl Knight, Philip Hansbro, Malcolm Starkey
2014 Fathi F, Hsu A, Parsons K, Keely S, Wood L, Wark P, 'OXIDATIVE STRESS IMPAIRS MITOCHONDRIAL FUNCTION AND LEADS TO DEFICIENT ANTIVIRAL RESPONSES IN PRIMARY BRONCHIAL EPITHELIAL CELLS', RESPIROLOGY (2014) [E3]
DOI 10.1111/resp.12263_3
Co-authors Simon Keely, Alan Hsu, Lisa Wood
2014 Collison A, Hatchwell L, Girkin J, Li J, Parsons K, Bartlett N, et al., 'REDUCED TLR7 EXPRESSION MAY UNDERPIN IMPAIRED RESPONSE TO VIRAL INFECTION IN ASTHMA', RESPIROLOGY (2014) [E3]
DOI 10.1111/resp.12263_5
Co-authors Adam Collison, Paul Foster, Joerg Mattes
2014 Hsu A, Parsons K, Hansbro P, Wark P, Wark P, 'IMPAIRED FORMATION OF ANTIVIRAL STRESS GRANULE AND INTERFERON-BETA ENHANCEOSOME LEADS TO REDUCED ANTIVIRAL RESPONSES TO INFLUENZA IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE', RESPIROLOGY (2014) [E3]
Co-authors Philip Hansbro, Alan Hsu
2014 Saleem TA, Mcdonald M, Sankaranarayanan A, Schofield P, Wark P, 'PREVALENCE AND IMPACT OF COGNITIVE IMPAIRMENT IN COPD', RESPIROLOGY (2014) [E3]
Co-authors Vanessa Mcdonald, Peter Schofield
2014 Wark PPW, Tolosa JMJT, Parsons K, Smith R, 'The placental derived protein syncytin-1 impairs antiviral responses and exaggerates inflammatory responses to influenza', Cytokine (2014) [E3]
DOI 10.1016/j.cyto.2014.07.154
Co-authors Roger Smith
2014 Tolosa JM, Parsons K, Wark P, Smith R, 'HOW THE PLACENTA MAKES PREGNANT WOMEN VULNERABLE TO INFLUENZA (FLU)', PLACENTA (2014) [E3]
Co-authors Roger Smith
2013 Hansbro P, Beckett E, Stevens R, Jarnicki A, Kim R, Hanish I, et al., 'A short-term model of COPD identifies a role for mast cell tryptase', JOURNAL OF IMMUNOLOGY (2013) [E3]
Co-authors Paul Foster, Jay Horvat, Simon Keely, Nicole Hansbro, Philip Hansbro, Ming Yang
2013 Forbes RL, Gibson PG, Murphy VE, Wark PA, 'H1N1PDM09 ALTERS MATERNAL IMMUNITY DURING PREGNANCY', RESPIROLOGY (2013) [E3]
Co-authors Vanessa Murphy, Peter Gibson
2013 Zhong H, Simpson JL, Wood LG, Wark PAB, 'COPD PERIPHERAL BLOOD NEUTROPHILS HAVE ENHANCED RELEASE OF IL-1B WHEN STIMULATED', RESPIROLOGY (2013) [E3]
Co-authors Lisa Wood, Jodie Simpson
2012 Patel S, McKay K, Cooper P, Sorrell T, Andresen D, Middleton P, et al., 'Fungal colonisation and clinical associations in children with cystic fibrosis', Mycoses (2012) [E3]
2012 Addnan FH, Wood LG, Garg ML, Wark PA, 'Antiviral effects of antioxidants on human rhinovirus', Respirology (2012) [E3]
Co-authors Manohar Garg, Lisa Wood
2012 Hsu A, Parsons KS, Barr I, Hansbro PM, Wark PA, 'Deficient antiviral responses to influenza in primary bronchial epithelial cells of chronic obstructive pulmonary disease', Respirology (2012) [E3]
Co-authors Alan Hsu, Philip Hansbro
2012 McDonald VM, Wark PA, Roberts M, Spencer LM, Alison JA, Wood LG, Gibson PG, 'Development and audience testing of a COPD education DVD', Respirology (2012) [E3]
Co-authors Peter Gibson, Vanessa Mcdonald, Lisa Wood
2012 Zhong H, Simpson JL, Wood LG, Wark PA, 'Activation of human neutrophils exposed to cigarette smoke extract: A comparison of COPD patients versus healthy non-smokers', Respirology (2012) [E3]
Co-authors Jodie Simpson, Lisa Wood
2012 Parsons KS, Tooze MK, Grissell TV, Bell N, Chapman JN, Ryan J, et al., 'Patterns (2007-2009) of respiratory viruses isolated from acute exacerbations of airways disease', Respirology (2012) [E3]
Co-authors Peter Gibson
2012 See HV, Simpson JL, Hansbro PM, Wark PA, 'Stable COPD patients have less rhinovirus-induced intracellular innate cytokines detected in PBMCS compared to healthy adults', Respirology (2012) [E3]
Co-authors Jodie Simpson, Philip Hansbro
2012 Wark PA, Tooze MK, Cheese L, Whitehead BF, Gibson PG, McDonald VM, 'Viral infections trigger CF exacerbations and worsen infection with P Aeruginosa in adults and children', Respirology (2012) [E3]
Co-authors Vanessa Mcdonald, Peter Gibson
2012 Wark PA, Tooze MK, Hsu A, Parsons KS, 'Silencing of MDA5 and TLR3 does not reduce innate immune responses to rhinovirus in defective asthmatic bronchial epithelial cells', Respirology (2012) [E3]
Co-authors Alan Hsu
2012 Zhong H, Simpson JL, Wood LG, Wark PA, 'Different responses of blood neutrophils from COPD', Respirology (2012) [E3]
Co-authors Jodie Simpson, Lisa Wood
2011 Addnan FH, Wark PA, Wood LG, Garg ML, 'Antiviral activity of antioxidants against rhinovirus infection', Australasian Medical Journal (2011) [E3]
Co-authors Lisa Wood, Manohar Garg
2011 Addnan FH, Wark PA, Wood LG, Garg ML, 'Effects of antioxidants on inflammation and apoptosis in rhinovirus-infected airway epithelial cells', Australasian Medical Journal (2011) [E3]
Co-authors Lisa Wood, Manohar Garg
2011 Smart JM, Wark PA, Wood LG, 'Investigating the obesity paradox in ex-smokers', Australasian Medical Journal (2011) [E3]
Co-authors Lisa Wood
2011 Bozinovski S, Uddin M, Vlahos R, Thompson M, Merritt A-S, Wark PA, et al., 'Serum amyloid A augments mucosal immunity by opposing resolving Lipoxina4 signaling in chronic lung disease', American Journal of Respiratory and Critical Care Medicine (2011) [E3]
2011 Sukkar MB, Wood LG, Tooze MK, Simpson JL, McDonald VM, Gibson PG, Wark PA, 'Deficiency of srage in asthma and COPD is selectively associated with neutrophilic airway inflammation', American Journal of Respiratory and Critical Care Medicine (2011) [E3]
Co-authors Lisa Wood, Peter Gibson, Vanessa Mcdonald, Jodie Simpson
2011 Sukkar M, Wood LG, Tooze MK, Simpson JL, McDonald VM, Gibson PG, Wark PA, 'Soluble RAGE is deficient in neutrophilic asthma and COPD', Respirology (2011) [E3]
DOI 10.1183/09031936.00022011
Citations Scopus - 57Web of Science - 48
Co-authors Jodie Simpson, Peter Gibson, Lisa Wood, Vanessa Mcdonald
2011 Baines KJ, Tooze MK, Wark PA, 'Rhinovirus infected airway epithelial cells have an increased pro-inflammatory response in COPD', Respirology (2011) [E3]
Co-authors Katherine Baines
2011 Vanders RL, Gibson PG, Murphy VE, Wark PA, 'Reduced antiviral interferons during pregnancy explains susceptibility to influenza virus infection', Respirology (2011) [E3]
Co-authors Peter Gibson, Vanessa Murphy
2011 Parsons KS, Tooze MK, Hsu A, Wark PA, 'Oxidative stress induces mitochondrial dusfunction in airway epithelial cells and impairs response to rhinovirus', Respirology (2011) [E3]
Co-authors Alan Hsu
2011 Ryan NM, Vertigan AE, Ferguson JK, Wark PA, Gibson PG, 'Investigation and characterization of persistent cough associated with H1N1 2009 influenza', Respirology (2011) [E3]
Co-authors John Ferguson, Peter Gibson, Nicole Ryan
2011 See HV, Simpson JL, Hansbro PM, Wark PA, 'COPD patients PBMCS have an impaired immune response to phinovirus-infected bronchial epithelium', Respirology (2011) [E3]
Co-authors Jodie Simpson, Philip Hansbro
2011 Wark PA, Parsons KS, Tooze MK, Hsu A, 'MDA5 is crucial inhibiting rhinovirus replication in primary bronchial epithelial cells', Respirology (2011) [E3]
Co-authors Alan Hsu
2011 Zhong H, Tooze MK, Wood LG, Simpson JL, Wark PA, 'Effect of cigarette smoke extract on neutrophils isolated from human peripheral blood', Respirology (2011) [E3]
Co-authors Lisa Wood, Jodie Simpson
2011 Hatchwell LM, Collison AM, Pereira De Siqueira AL, Foster PS, Verrills NM, Don A, et al., 'A novel E3 ubiquitin ligase links rhinovirus infection to exacerbation of asthma', Respirology (2011) [E3]
Co-authors Joerg Mattes, Nikki Verrills, Paul Foster, Adam Collison
2010 Smart JM, Wark PA, McDonald VM, Wood LG, 'Body composition in ex-smokers with and without airflow obstruction', Obesity Research and Clinical Practice (2010) [E3]
Co-authors Vanessa Mcdonald, Lisa Wood
2010 Smart JM, Wark PA, McDonald VM, Wood LG, 'Low levels of body fat and obstructive airway disease in ex-smokers', Proceedings of the Nutrition Society of Australia (2010) [E3]
Co-authors Lisa Wood, Vanessa Mcdonald
2010 Pretto JJ, McDonald VM, Wark PA, Hensley MJ, 'An audit of clinical practice for COPD hospital admissions to eight Australian public hospitals', European Respiratory Society Annual Congress 2010. Abstracts (2010) [E3]
Co-authors Vanessa Mcdonald, Michael Hensley
2010 Vanders RL, Gibson PG, Murphy VE, Wark PA, 'Reduced anti-viral responses: Why pregnant women have increased susceptibility to respiratory virus infection', American Journal of Respiratory and Critical Care Medicine (2010) [E3]
Co-authors Vanessa Murphy, Peter Gibson
2010 Vanders RL, Gibson PG, Murphy VE, Wark PA, 'Reduced anti-viral responses: Why pregnant women have increased susceptiblty to respiratory virus infection', Respirology (2010) [E3]
Co-authors Vanessa Murphy, Peter Gibson
2010 Gangireddy SR, Parsons KS, Tooze MK, Wark PA, 'The innate immune response to rhinovirus in bronchial epithelial cells is predominately controlled by signalling initiated via MDA-5', Respirology (2010) [E3]
2010 McDonald VM, Pretto JJ, Wark PA, Hensley MJ, 'Low acuity COPD admissions: Are they avoidable?', Respirology (2010) [E3]
Co-authors Vanessa Mcdonald, Michael Hensley
2010 Parsons KS, Tooze MK, Gangireddy SR, Wark PA, 'Cigarette smoke extract impairs epithelial cell antiviral response to rhinovirus infection', Respirology (2010) [E3]
2010 Pretto JJ, McDonald VM, Wark PA, Hensley MJ, 'An audit of clinical practice for COPD hospital admissions', Respirology (2010) [E3]
Co-authors Michael Hensley, Vanessa Mcdonald
2010 Smart JM, Wark PA, McDonald VM, Wood LG, 'CRP, body composition and lung function in ex-smokers', Respirology (2010) [E3]
Co-authors Vanessa Mcdonald, Lisa Wood
2010 Yan X, He S, Gangireddy SR, Gibson PG, Wark PA, 'Monocyte derived dendritic cells from COPD patients and their therapeutic potential', Respirology (2010) [E3]
Co-authors Peter Gibson
2009 Southern KW, Smyth A, Wark PA, Ryan G, Dwan K, Yates N, et al., 'The impact of Cochrane systematic reviews on cyctic fibrosis care', Pediatric Pulmonology (2009) [E3]
DOI 10.1002/ppul.21133
2009 Wark PA, Hsu A, Hansbro PM, 'Innate immune response of bronchial epithelial cells to infection with influenza', Journal of Immunology (2009) [E3]
Co-authors Alan Hsu, Philip Hansbro
2009 Wark PA, See HV, Simpson JL, Vanders RL, Hansbro PM, 'Peripheral blood monocytes (PBMCs) display innate antiviral response to rhinovirus (RV) infected bronchial epithelial cells', Journal of Immunology (2009) [E3]
Co-authors Jodie Simpson, Philip Hansbro
2009 Addnan FH, Wood LG, Garg ML, Wark PA, 'Resveratrol prevents hydrogen peroxide induced cytotoxicity', Proceedings of the Nutrition Society of Australia (2009) [E3]
Co-authors Lisa Wood, Manohar Garg
2009 Foo A, Lam CE, Wark PA, Foster PS, Phipps S, 'Immune mechanisms that promote the development of inducible bronchus-associated lymphoid tissue (iBALT)', American Journal of Respiratory and Critical Care Medicine (2009) [E3]
Co-authors Paul Foster
2009 Parsons KS, Gangireddy SR, Hansbro PM, Barr I, Wark PA, 'Response of primary bronchial epithelial cells to infection with human influenza virus', Respirology (2009) [E3]
DOI 10.1111/j.1440-1843.2009.01502_7.x
Co-authors Philip Hansbro
2009 Wark PA, Parsons KS, Ryan J, Grissell T, Bell N, Chapman JN, Gibson PG, 'Seasonal patterns (2004-2007) of respiratory viruses isolated with acute airways disease', Respirology (2009) [E3]
DOI 10.1111/j.1440-1843.2009.01503_1.x
Co-authors Peter Gibson
2009 Twaddell S, Loewenthal MR, Gibson PG, Saltos N, Wark PA, 'Individualised aminoglycoside dosing in adult patients with cystic fibrosis improves pharmacokinetic parameters', Respirology (2009) [E3]
DOI 10.1111/j.1440-1843.2009.01503_1.x
Co-authors Peter Gibson
2009 Baines KJ, Grissell TV, Gibson PG, Wark PA, 'Molecular mechanisms of rhinovirus infection of primary bronchial epithelial cells', Respirology (2009) [E3]
DOI 10.1111/j.1440-1843.2009.01503_1.x
Co-authors Peter Gibson, Katherine Baines
2009 Clarke J, Cookson K, Gendle L, Bentley L, Wark PA, McDonald VM, 'Evaluation of patient acceptance of CF segregation and isolation policies', Respirology (2009) [E3]
DOI 10.1111/j.1440-1843.2009.01502_7.x
Co-authors Vanessa Mcdonald
2009 Wark PA, Oldham RA, Brooks C, Simpson JL, Douwes J, 'Airway neutrophilia in chronic obstructive pulmonary disease (COPD) and asthma are associated with lower lung function and the presence of pathogenic bacteria', Respirology (2009) [E3]
DOI 10.1111/j.1440-1843.2009.01502_7.x
Co-authors Jodie Simpson
2009 Hsu A, Hansbro PM, Barr I, Wark PA, 'Innate immune response of bronchial epithelial cells to human and avian influenza virus', Respirology (2009) [E3]
Co-authors Philip Hansbro, Alan Hsu
2008 Oliver BGG, Kuo C, Johnston SL, King NJC, Wark PA, Lim S, et al., 'Rhinovirus infection of primary human airway smooth muscle cells and fibroblasts induces extracellular matrix deposition', American Journal of Respiratory and Critical Care Medicine (2008) [E3]
2008 Wark PA, Davies BL, Parsons KS, Grissell T, 'Impaired release of inflammatory mediators from COPD bronchial epithelial cells (BECs) in response to rhinovirus (RV) and lipopolysaccharide (LPS)', Respirology (2008) [E3]
DOI 10.1111/j.1440-1843.2008.01252.x
2008 Wark PA, Oldham RA, Simpson JL, Douwes J, 'Endotoxin levels are higher in the bronchoalveolar lavage of ex-smokers compared to never smokers', Respirology (2008) [E3]
DOI 10.1111/j.1440-1843.2008.01252.x
Co-authors Jodie Simpson
2008 Hsu A, Grissell TV, Wark PA, 'Distribution of SAa2,6GAL and SAa2,3GAL linked receptors in human respiratory tract and influenza virus replication', Respirology (2008) [E3]
DOI 10.1111/j.1440-1843.2008.01252_13.x
Co-authors Alan Hsu
2008 Osei-Kumah A, Wark PA, Smith R, Ammit A, Clifton VL, 'A model of pregnancy induced changes in asthma', 51st Annual Scientific Meeting of the Endocrine Society of Australia and Society of Reproductive Biology: Meeting Proceedings and Abstract Book (2008) [E3]
Co-authors Roger Smith, Vicki Clifton
2008 Hsu A, Hansbro PM, Wark PA, 'Innate immune response of bronchial epithelial cells to human and avian influenza virus', The 4th Congress of the Federation of Immunology Societies of Asia-Oceania: Conference Program (2008) [E3]
Co-authors Philip Hansbro, Alan Hsu
2007 Grissell TV, Hansbro NG, Hsu A, Mimica J, Wark PA, 'Response of primary bronchoepithelial cells from COPD, asthmatic and healthy subjects to infection with avian and human influenza virus strains', Respirology (Abstracts of the 12th Congress of the Asian Pacific Society of Respirology) (2007) [E3]
Co-authors Nicole Hansbro
2007 De Groot RS, Kuo C, King N, Moir L, Lim S, Burgess JK, et al., 'Steroids can reverse rhinovirus-induced alterations to bronchial epithhelium extracellular matrix deposition', Respirology (Abstracts of the 12th Congress of the Asian Pacific Society of Respirology) (2007) [E3]
2007 Reddel HK, Peters MJ, Wark PA, Sand IB, Jenkins CR, 'Comparison of the efficacy of seretide and flixotide when down-titrating the inhaled corticosteroid dose', American Journal of Respiratory and Critical Care Medicine (American Thoracic Society 2007 International Conference Abstracts) (2007) [E3]
2007 Xatzipsalti M, Haynes R, Ribbene A, Sones JL, Bagmane D, Wark PA, et al., 'Deficient interferon production following rhinovirus infection of differentiated bronchial epithelial cells from asthmatic subjects', American Journal of Respiratory and Critical Care Medicine (American Thoracic Society 2007 International Conference Abstracts) (2007) [E3]
2007 Wark PA, See HV, Oldham R, Timmins N, Gibson PG, Hansbro PM, 'Response by peripheral blood monocytes (PBMCs) to rhinovirus (RV) is greater in cells exposed to infected epithelium in coculture than exposed to RV alone', American Journal of Respiratory and Critical Care Medicine (American Thoracic Society 2007 International Conference Abstracts) (2007) [E3]
Co-authors Philip Hansbro, Peter Gibson
2007 Wark PA, Grissell TV, Davies B, Mimica J, Oldham R, Shafren DR, Gibson PG, 'Bronchial epithelial cell (BEC) response to clinical rhinovirus (clin-RV) isolates from ASTHMATICS compared to laboratory (lab-RV) strains', American Journal of Respiratory and Critical Care Medicine (American Thoracic Society 2007 International Conference Abstracts) (2007) [E3]
Co-authors Peter Gibson
2007 Ribbene A, Bucchieri F, Wark PA, Andrews AL, Puddicombe SM, Zummo G, et al., 'Epithelial-mesenchymal communication following rhinovirus infection of asthmatic bronchial epithelial cells', American Journal of Respiratory and Critical Care Medicine (American Thoracic Society 2007 International Conference Abstracts) (2007) [E3]
2007 Saedi Some Olia A, Garg ML, Wood LG, Wark PA, Gibson PG, 'Lycopene enrichment of cultured epithelial airway cells', Asia Pacific Journal of Clinical Nutrition (2007) [E3]
Co-authors Peter Gibson, Lisa Wood, Manohar Garg
2007 Saedi Some Olia A, Garg ML, Wood LG, Gibson PG, Wark PA, 'Anti-inflammatory effect of lycopene enrichment on infected cultured airway epithelial cells', Respirology (Abstracts of the 12th Congress of the Asian Pacific Society of Respirology) (2007) [E3]
Co-authors Lisa Wood, Peter Gibson, Manohar Garg
2007 See H, Oldham R, Timmins N, Hansbro PM, Wark PA, Gibson PG, 'Rhinovirus (RV) induced inflammatory response in mononuclear cells is enhanced by coculture with airway epithelium', Respirology (TSANZ Abstracts-Posters) (2007) [E3]
DOI 10.1111/j.1440-1843.2007.001050.x
Co-authors Peter Gibson, Philip Hansbro
2007 Wark PA, Mimica J, Oldham R, Davies DE, Holgate SE, Johnston S, Gibson PG, 'Interferon-G induced protein (IP)- 10 is a novel clinical biomarker of rhinovirus (RV)-induced asthma exacerbations', Respirology (TSANZ Abstracts-Posters) (2007) [E3]
Co-authors Peter Gibson
2007 Jenkins CR, Marks GB, Gibson PG, Wark PA, Thien FCK, Belousova EG, et al., 'A randomised controlled trial of two algorithms for maintaining asthma control on long acting bronchodilators (LABA) and inhaled corticosteroids (ICS)', Respirology (TSANZ Abstracts-Posters) (2007) [E3]
Co-authors Peter Gibson
2006 Grissell TV, Davies B, Mimica JL, Shafren DR, Gibson PG, Wark PA, 'Bronchial epithelial cell response to clinical rhinoviruses isolated from asthmatics compared to laboratory rhinovirus strains', Respirology (2006) [E3]
Co-authors Peter Gibson
2006 Wark PA, Wood LG, Grissell TV, Davies B, Shafren DR, Powell HG, et al., 'Acute virus-induced asthma is characterised by increased expression of toll-like receptors (TLR)-2', Respirology (2006) [E3]
Co-authors Lisa Wood, Peter Gibson, Michael Hensley
2004 Wark PAB, Johnston SL, Bucchieri F, Powell R, Puddicombe S, Laza-Stanca V, et al., 'Asthmatic bronchial epithelial cells have deficient innate immune response to infection with rhinovirus', THORAX (2004)
2003 Wark PAB, Buccheri F, Puddicombe S, Johnston SJ, Holgate ST, Davies DE, 'Asthmatic bronchial epithelial cells (BEC) are more resistant to early apoptosis induced by rhinovirus (RV) and this is associated with increased viral replication', THORAX (2003)
2003 Wark PAB, Bucchieri F, Puddicombe SM, Andrews AL, Johnston SL, Davies DE, Holgate ST, 'Cytotoxic effects of infection with rhinovirus on asthmatic primary bronchial epithelial cells', EUROPEAN RESPIRATORY JOURNAL (2003)
2002 Wark PAB, Puddicombe SM, Frew AJ, Holgate ST, Davies DE, 'Determinants of cytotoxicity of residual oil fly ash (ROFA) on bronchial epithelial cells', THORAX (2002)
2001 Wark P, Simpson JL, Saltos N, Hensley MJ, Gibson PC, 'Itraconazole reduces eosinophilic airway inflammation in allergic bronchopulmonary aspergillosis (abpa)', Respirology (2001)

ABPA is an important complication of chronic asthma resulting from hypersensitivity to the fungus Aspergillus Fumigatus ( AF}. ABPA is characterised by an intense immune response ... [more]

ABPA is an important complication of chronic asthma resulting from hypersensitivity to the fungus Aspergillus Fumigatus ( AF}. ABPA is characterised by an intense immune response with increased use of oral steroids and potentially progressive lung disease. The aim of this study was to determine if treatment of subjects with ABPA with the antifungal agent Itraconazole (Itz) reduced airway and systemic inflammation. Methods: A randomised double blind placebo controlled trial was performed in stable subjects with ABPA (n=29). Subjects with cystic fibrosis ere excluded. The diagnosis of ABPA was based upon; the presence of asthma, IgE sensitisation to Af. a total serum IgE of lOOOIl'/mL or greater and serum IgG to Af or central bronchiectasis on CT scan. Subjects received Itz 400mg per day (n=15) or placebo (n=14) for 16 weeks. All subjects were reviewed monthly with history, spirometry. sputum induction to measure airway inflammation, serum total IgE and IgG to Af and blood eosinophils. Results: Subjects receiving Itz had a greater reduction in sputum eosinophils from baseline (median fall of 94.5%) compared to placebo (45.4%. p<0.01 ). Those on Itz had a fall in sputum total cell count from baseline (43.9%) compared to a rise in those on placebo (rise 10%. p=0.049). Subjects that received Itz also had a reduction in systemic immune activation; there was a fall in serum IgE (3IOIU/mL) compared to placebo (rise ISIU-'mL, p<0.01) and a fall in IgG to Af(15.4IU/mL) compared to placebo (rise 3.7IU-mL, p=0.03). Conclusion: Treatment of subjects with stable ABPA with Itz 400mg daily reduces eosinophilic airway inflammation along with measures of systemic immune activation. These results imply that Itz is a potential adjunctive treatment for ABPA and this should be further investigated with larger studies of lone term clinical efficacv.

Co-authors Jodie Simpson, Michael Hensley, Peter Gibson
Show 97 more conferences

Creative Work (1 outputs)

Year Citation Altmetrics Link
2011 McDonald VM, Wark PA, Gibson PG, Alison J, Spencer L, Wood LG, Roberts M, Living with COPD: Chronic Obstructive Pulmonary Disease, Newcastle (2011) [J2]
Co-authors Vanessa Mcdonald, Peter Gibson, Lisa Wood
Edit

Grants and Funding

Summary

Number of grants 55
Total funding $13,288,889

Click on a grant title below to expand the full details for that specific grant.


20168 grants / $1,971,401

Role and potential for therapeutic targeting of dysfunction, oxidative stress and altered metabolism in mitochondria in the pathogenesis of COPD$722,842

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Professor Phil Hansbro, Conjoint Professor Peter Wark, Professor Ian Adcock, Professor Luke O'Neill
Scheme Project Grant
Role Investigator
Funding Start 2016
Funding Finish 2019
GNo G1500070
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

How the placental protein Syncytin impairs maternal immune responses to influenza$612,881

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Conjoint Professor Peter Wark, Laureate Professor Roger Smith, Doctor Jay Horvat
Scheme Project Grant
Role Lead
Funding Start 2016
Funding Finish 2018
GNo G1500388
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

Identification of genomic mutations associated with the development and progression of lung cancer for use in early diagnosis$360,000

Funding body: Cancer Council NSW

Funding body Cancer Council NSW
Project Team Professor Phil Hansbro, Conjoint Professor Peter Wark, Professor David Watkins, Dr Warren Kaplan
Scheme Research Grant
Role Investigator
Funding Start 2016
Funding Finish 2018
GNo G1500465
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

Inhibition of rhinovirus-induced disease by TLR2 agonist$193,933

Funding body: Innavac

Funding body Innavac
Project Team Doctor Nathan Bartlett, Conjoint Professor Peter Wark
Scheme Research Grant
Role Investigator
Funding Start 2016
Funding Finish 2016
GNo G1600747
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

Molecular phenotyping in severe asthma$21,745

Funding body: John Hunter Hospital Charitable Trust

Funding body John Hunter Hospital Charitable Trust
Project Team Doctor Douglas Dorahy, Conjoint Professor Peter Wark, Miss Stephany Sanchez Ovando
Scheme Research Grant
Role Investigator
Funding Start 2016
Funding Finish 2016
GNo G1600528
Type Of Funding Other Public Sector - State
Category 2OPS
UON Y

Managing Inflammation in COPD (MiCOPD)$20,000

Funding body: Lung Foundation Australia

Funding body Lung Foundation Australia
Project Team Professor Vanessa McDonald, Conjoint Professor Peter Gibson, Associate Professor Jodie Simpson, Conjoint Professor Peter Wark
Scheme Boehringer Ingelheim COPD Research Top-Up Grant
Role Investigator
Funding Start 2016
Funding Finish 2017
GNo G1601013
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

Inflammation based management of severe asthma: utility of blood oesinophils$20,000

Funding body: National Clinical CRE in Severe Asthma

Funding body National Clinical CRE in Severe Asthma
Project Team Conjoint Professor Peter Wark, Associate Professor Jodie Simpson, Professor Vanessa McDonald, Conjoint Professor Peter Gibson, Conjoint Associate Professor Christopher Grainge
Scheme Seed Research Project
Role Lead
Funding Start 2016
Funding Finish 2016
GNo G1601079
Type Of Funding Internal
Category INTE
UON Y

RCT of the efficacy and safety of an ICS/ LABA reliever therapy regimen in asthma$20,000

Funding body: Woolcock Institute of Medical Research

Funding body Woolcock Institute of Medical Research
Project Team Associate Professor Jodie Simpson, Conjoint Professor Peter Wark
Scheme Research Project
Role Investigator
Funding Start 2016
Funding Finish 2016
GNo G1601147
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

20154 grants / $1,252,644

Modifying epigenetics as a novel treatment in COPD$1,087,422

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Professor Phil Hansbro, Professor Darryl Knight, Conjoint Professor Peter Wark, Professor Ian Adcock
Scheme Project Grant
Role Investigator
Funding Start 2015
Funding Finish 2019
GNo G1400006
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

Improving diet quality to reduce risk of asthma attacks in children$120,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Associate Professor Lisa Wood, Professor Joerg Mattes, Conjoint Professor Peter Wark, Doctor Katie Baines, Doctor Megan Jensen
Scheme Project Grant
Role Investigator
Funding Start 2015
Funding Finish 2016
GNo G1500957
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

Enhanced oxidative stress impairs mitochondrial function and antiviral responses to rhinovirus infection in asthma and chronic obstructive pulmonary disease$25,222

Funding body: John Hunter Hospital Charitable Trust

Funding body John Hunter Hospital Charitable Trust
Project Team Doctor Alan Hsu, Conjoint Professor Peter Wark, Miss Kristy Nichol
Scheme Research Grant
Role Investigator
Funding Start 2015
Funding Finish 2015
GNo G1500012
Type Of Funding Other Public Sector - State
Category 2OPS
UON Y

How oxidative stress makes severe asthmatics susceptible to infection with Rhinovirus$20,000

Funding body: National Clinical CRE in Severe Asthma

Funding body National Clinical CRE in Severe Asthma
Project Team Conjoint Professor Peter Wark, Associate Professor Lisa Wood, Professor Phil Hansbro, Mr Prabuddha Pathinayake
Scheme Seed Research Project
Role Lead
Funding Start 2015
Funding Finish 2015
GNo G1600355
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

20145 grants / $3,315,596

National Clinical Centre of Research Excellence in Severe Asthma$2,550,836

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Conjoint Professor Peter Gibson, Professor Guy Marks, Professor Vanessa McDonald, Conjoint Professor Peter Wark, Conjoint Associate Professor Greg King, Dr Bruce Thompson, Associate Professor Helen Reddel, Professor John Upham, Dr Lorraine Smith, Professor Alan James
Scheme Centres of Research Excellence (CRE) - Centres of Clinical Research Excellence
Role Investigator
Funding Start 2014
Funding Finish 2019
GNo G1400017
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

Toll-like receptor 7 and asthma $697,248

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Professor Joerg Mattes, Laureate Professor Paul Foster, Conjoint Professor Peter Wark
Scheme Project Grant
Role Investigator
Funding Start 2014
Funding Finish 2016
GNo G1300093
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

Mechanisms of dysregulated antiviral signallings to influenza infection in chronic obstructive pulmonary disease$27,512

Funding body: John Hunter Hospital Charitable Trust

Funding body John Hunter Hospital Charitable Trust
Project Team Doctor Alan Hsu, Doctor Fatemeh Moheimani, Professor Darryl Knight, Conjoint Professor Peter Wark
Scheme Research Grant
Role Investigator
Funding Start 2014
Funding Finish 2014
GNo G1400435
Type Of Funding Other Public Sector - State
Category 2OPS
UON Y

Immunosenescence in chronic obstructive pulmonary disease leads to abnormal innate immune responses to human rhinovirus infection$20,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Conjoint Professor Peter Wark, Professor Darryl Knight
Scheme Project Grant
Role Lead
Funding Start 2014
Funding Finish 2014
GNo G1301331
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

Predicting who is at risk of worsening lung disease in Cystic Fibrosis$20,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Conjoint Professor Peter Wark, Doctor Katie Baines, Professor Vanessa McDonald, Conjoint Professor Peter Gibson, Associate Professor Scott Bell, Dr David Reid
Scheme Project Grant
Role Lead
Funding Start 2014
Funding Finish 2014
GNo G1401410
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

20135 grants / $1,295,433

Inflammometry in Stable COPD; A Randomised Controlled Trial (RCT)$717,071

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Conjoint Professor Peter Gibson, Professor Vanessa McDonald, Associate Professor Jodie Simpson, Conjoint Professor Peter Wark
Scheme Project Grant
Role Investigator
Funding Start 2013
Funding Finish 2016
GNo G1200185
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

Enhancing innate immune responses to influenza in chronic obstructive pulmonary disease$504,552

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Conjoint Professor Peter Wark, Professor Phil Hansbro, Professor James Mahony
Scheme Project Grant
Role Lead
Funding Start 2013
Funding Finish 2015
GNo G1200206
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

BD FACSCanto II Violet Laser (405nm) upgrade including Trigon and 2 photomultiplier tubes (PMTs)$25,000

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Conjoint Professor Peter Wark, Doctor Alan Hsu, Doctor Katie Baines, Associate Professor Jodie Simpson, Conjoint Professor Peter Gibson, Ms Hayley See
Scheme Equipment Grant
Role Lead
Funding Start 2013
Funding Finish 2013
GNo G1201180
Type Of Funding Other Public Sector - Commonwealth
Category 2OPC
UON Y

Protecting Pregnant Women from Death during influenza epidemics$25,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Laureate Professor Roger Smith, Professor Phil Hansbro, Conjoint Professor Peter Wark
Scheme Project Grant
Role Investigator
Funding Start 2013
Funding Finish 2013
GNo G1301181
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

Mechanisms of impaired antiviral interferon response to influenza infection in primary bronchial epithelial cells from chronic obstructive pulmonary disease$23,810

Funding body: John Hunter Hospital Charitable Trust

Funding body John Hunter Hospital Charitable Trust
Project Team Doctor Alan Hsu, Conjoint Professor Peter Wark
Scheme Research Grant
Role Investigator
Funding Start 2013
Funding Finish 2013
GNo G1300711
Type Of Funding Other Public Sector - State
Category 2OPS
UON Y

20121 grants / $33,076

Body plethysmograph respiratory function system$33,076

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Conjoint Professor Peter Gibson, Conjoint Professor Peter Wark, Associate Professor Lisa Wood, Associate Professor Jodie Simpson, Doctor Katie Baines, Doctor Vanessa Murphy, Doctor Jeffrey Pretto, Emeritus Professor Michael Hensley, Ms Jenny Mackney
Scheme Equipment Grant
Role Investigator
Funding Start 2012
Funding Finish 2012
GNo G1100973
Type Of Funding Other Public Sector - Commonwealth
Category 2OPC
UON Y

20117 grants / $1,975,247

Identifying new therapeutic targets for preventing the induction and progression of COPD$626,732

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Professor Phil Hansbro, Conjoint Professor Peter Wark
Scheme Project Grant
Role Investigator
Funding Start 2011
Funding Finish 2013
GNo G1000252
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

Role of Placental Retroviral Protein Syncytin Carried on Exosomes in Mediating Vulnerability of Pregnant Women to Influenza$622,968

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Laureate Professor Roger Smith, Conjoint Professor Peter Wark
Scheme Project Grant
Role Investigator
Funding Start 2011
Funding Finish 2013
GNo G1000294
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

Understanding the mechanisms of respiratory viral infection- and COPD-induced predisposition to secondary bacterial pneumonia $573,390

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Professor Phil Hansbro, Conjoint Professor Peter Wark
Scheme Project Grant
Role Investigator
Funding Start 2011
Funding Finish 2013
GNo G1000248
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

Research microscope, confocal ready nikon eclipse 90i microscope$69,157

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Laureate Professor Roger Smith, Conjoint Professor Tamas Zakar, Professor Jon Hirst, Doctor Kaushik Maiti, Doctor Gemma Madsen, Professor Rodney Scott, Conjoint Professor Peter Wark, Laureate Professor Paul Foster, Professor Phil Hansbro, Conjoint Professor Ian Wright
Scheme Equipment Grant
Role Investigator
Funding Start 2011
Funding Finish 2011
GNo G1100024
Type Of Funding Other Public Sector - Commonwealth
Category 2OPC
UON Y

SCIREQ FlexiVentFX system + FlexiVentFX extension$45,000

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Professor Phil Hansbro, Laureate Professor Paul Foster, Professor Joerg Mattes, Doctor Simon Keely, Doctor Jay Horvat, Doctor Nicole Hansbro, Doctor Ming Yang, Doctor Catherine Ptaschinski, Doctor Kelly Asquith, Doctor Gough Au, Conjoint Professor Peter Wark, Laureate Professor John Aitken, Conjoint Professor Keith Jones, Laureate Professor Roger Smith, Professor Judith Black, Professor Rakesh Kumar, Professor Paul Hertzog
Scheme Equipment Grant
Role Investigator
Funding Start 2011
Funding Finish 2011
GNo G1100037
Type Of Funding Other Public Sector - Commonwealth
Category 2OPC
UON Y

To determine if asthmatics and children at risk of asthma that develop acute exacerbations have defective antiviral innate immune responses$28,000

Funding body: John Hunter Hospital Charitable Trust

Funding body John Hunter Hospital Charitable Trust
Project Team Conjoint Professor Peter Wark, Doctor Larry Roddick, Associate Professor Lisa Wood
Scheme Research Grant
Role Lead
Funding Start 2011
Funding Finish 2011
GNo G1100177
Type Of Funding Other Public Sector - State
Category 2OPS
UON Y

Lung Function (Spirometry) testing and sputum induction equipment - establishing 3 new clinical workstations. Medgraphics CPFS/d USB spirometer with breezesuite software (x3). Laptop computer (x3). Ul$10,000

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Conjoint Professor Peter Gibson, Associate Professor Jodie Simpson, Associate Professor Lisa Wood, Doctor Katie Baines, Conjoint Professor Peter Wark, Doctor Vanessa Murphy
Scheme Equipment Grant
Role Investigator
Funding Start 2011
Funding Finish 2011
GNo G1100038
Type Of Funding Other Public Sector - Commonwealth
Category 2OPC
UON Y

20102 grants / $59,000

Real time PCR machine (Mastercycler ep realplex2 from Epprndorf) $34,000

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Associate Professor Jodie Simpson, Conjoint Professor Peter Gibson, Conjoint Professor Peter Wark, Associate Professor Lisa Wood, Doctor Vanessa Murphy, Doctor Robert Scott, Doctor Katie Baines
Scheme Equipment Grant
Role Investigator
Funding Start 2010
Funding Finish 2010
GNo G1000056
Type Of Funding Other Public Sector - Commonwealth
Category 2OPC
UON Y

Identifying novel biomarkers of oxidative stress in chronic obstructive pulmonary disease$25,000

Funding body: Hunter Children`s Research Foundation

Funding body Hunter Children`s Research Foundation
Project Team Conjoint Professor Peter Wark, Associate Professor Lisa Wood
Scheme Research Grant
Role Lead
Funding Start 2010
Funding Finish 2010
GNo G0900145
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

20093 grants / $72,000

394591 ELx405UV select plate washer and workstation integration kit$27,500

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Conjoint Professor Peter Gibson, Doctor Xiao Yan He, Associate Professor Jodie Simpson, Associate Professor Lisa Wood, Conjoint Professor Peter Wark
Scheme Equipment Grant
Role Investigator
Funding Start 2009
Funding Finish 2009
GNo G0189853
Type Of Funding Other Public Sector - Commonwealth
Category 2OPC
UON Y

Development of novel therapeutic approaches for rhinovirus - induced asthma exacerbation$24,500

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Professor Joerg Mattes, Laureate Professor Paul Foster, Conjoint Professor Peter Wark
Scheme Project Grant
Role Investigator
Funding Start 2009
Funding Finish 2009
GNo G0189800
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

Treatment of subjects with cystic fibrosis who are colonised with aspergillus fumigatus$20,000

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Conjoint Professor Peter Wark, Associate Professor Scott Bell, Associate Professor Peter Bye, Associate Professor Adam Jaffe, Dr Hiran Selvadurai, Professor Phillip Robinson
Scheme Near Miss Grant
Role Lead
Funding Start 2009
Funding Finish 2009
GNo G0189818
Type Of Funding Internal
Category INTE
UON Y

20086 grants / $1,589,721

Inflammatory mechanisms of airways disease$1,064,500

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Conjoint Professor Peter Wark
Scheme Project Grant
Role Lead
Funding Start 2008
Funding Finish 2016
GNo G0189566
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

The mechanisms of infection of bronchial epithelial cells by human & avian influenza viruses in chronic airways disease$379,650

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Conjoint Professor Peter Wark, Professor Phil Hansbro, Dr Ian Barr
Scheme Project Grant
Role Lead
Funding Start 2008
Funding Finish 2010
GNo G0187593
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

The use of the components of the bacteria, streptococcus pneumoniae, as novel immunotherapies for asthma$50,000

Funding body: Asthma Foundation of New South Wales

Funding body Asthma Foundation of New South Wales
Project Team Professor Phil Hansbro, Professor Rakesh Kumar, Conjoint Professor Peter Wark
Scheme Research Grant
Role Investigator
Funding Start 2008
Funding Finish 2008
GNo G0188434
Type Of Funding Donation - Aust Non Government
Category 3AFD
UON Y

Mechanisms of inflammatory airways disease$40,571

Funding body: Markey Insurance

Funding body Markey Insurance
Project Team Conjoint Professor Peter Wark
Scheme HMRI Grant
Role Lead
Funding Start 2008
Funding Finish 2008
GNo G0189370
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

Becton Dickinson high throughout sampler for the FACSCanto II cytometry system$35,000

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Conjoint Professor Peter Wark, Conjoint Professor Peter Gibson, Associate Professor Jodie Simpson, Associate Professor Lisa Wood, Doctor Vanessa Murphy, Professor Phil Hansbro
Scheme Equipment Grant
Role Lead
Funding Start 2008
Funding Finish 2008
GNo G0188547
Type Of Funding Other Public Sector - Commonwealth
Category 2OPC
UON Y

PP2A: A new target for asthma therapy$20,000

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Professor Alistair Sim, Doctor Nikki Verrills, Professor John Scott, Conjoint Professor Peter Wark
Scheme Near Miss Grant
Role Investigator
Funding Start 2008
Funding Finish 2008
GNo G0188395
Type Of Funding Internal
Category INTE
UON Y

20078 grants / $546,848

Chronic Exposure of Bronchial Epithelial Cells to Bacterial Components Modifies their Innate Immune Response to Infection with Respiratory Viruses$313,500

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Conjoint Professor Peter Wark
Scheme Project Grant
Role Lead
Funding Start 2007
Funding Finish 2009
GNo G0186439
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

In vitro response of bronchial epithelial cells and activation of lymphocytes to infection with rhinovirus$58,848

Funding body: John Hunter Hospital Charitable Trust

Funding body John Hunter Hospital Charitable Trust
Project Team Conjoint Professor Peter Wark, Professor Phil Hansbro, Associate Professor Jodie Simpson
Scheme Research Grant
Role Lead
Funding Start 2007
Funding Finish 2009
GNo G0188095
Type Of Funding Donation - Aust Non Government
Category 3AFD
UON Y

Differential regulation of human mast cell degranulation by discrete forms of protein phosphatase 2A$50,000

Funding body: Asthma Foundation of New South Wales

Funding body Asthma Foundation of New South Wales
Project Team Professor Alistair Sim, Doctor Nikki Verrills, Laureate Professor Paul Foster, Conjoint Professor Peter Wark, Conjoint Professor Peter Gibson, Dr Gregory Kranias
Scheme Research Grant
Role Investigator
Funding Start 2007
Funding Finish 2007
GNo G0187247
Type Of Funding Donation - Aust Non Government
Category 3AFD
UON Y

Nitric Oxide Monitoring System (NIOX)$45,000

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Conjoint Professor Peter Gibson, Conjoint Associate Professor Vicki Clifton, Conjoint Professor Warwick Giles, Emeritus Professor Michael Hensley, Doctor Vanessa Murphy, Conjoint Professor Peter Wark, Professor Vanessa McDonald, Associate Professor Jodie Simpson, Conjoint Associate Professor Bruce Whitehead, Laureate Professor Paul Foster, Professor Phil Hansbro, Associate Professor Lisa Wood
Scheme Equipment Grant
Role Investigator
Funding Start 2007
Funding Finish 2007
GNo G0188193
Type Of Funding Other Public Sector - Commonwealth
Category 2OPC
UON Y

In vitro response of bronchial epithelial cells and activation of lymphocytes from COPD patients by infection with rhinovirus, respiratory syncytial virus and haemophilus influenza$25,000

Funding body: GlaxoSmithKline Australia

Funding body GlaxoSmithKline Australia
Project Team Conjoint Professor Peter Wark, Professor Phil Hansbro, Associate Professor Jodie Simpson
Scheme Support Grant
Role Lead
Funding Start 2007
Funding Finish 2008
GNo G0188309
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

Hewlett Packard 7890 series gas chromatograph with accessories$20,000

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Associate Professor Lisa Wood, Conjoint Professor Peter Wark, Conjoint Professor Peter Gibson, Associate Professor Jodie Simpson, Doctor Vanessa Murphy, Laureate Professor Paul Foster, Professor Phil Hansbro, Conjoint Associate Professor Vicki Clifton, Professor Clare Collins, Conjoint Professor Wayne Smith, Professor John Attia
Scheme Equipment Grant
Role Investigator
Funding Start 2007
Funding Finish 2007
GNo G0188191
Type Of Funding Other Public Sector - Commonwealth
Category 2OPC
UON Y

Class II biohazard containment hood and carbon dioxide cell culture incubator$20,000

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Conjoint Professor Peter Wark, Conjoint Professor Peter Gibson, Associate Professor Jodie Simpson, Doctor Vanessa Murphy, Associate Professor Lisa Wood, Laureate Professor Paul Foster, Professor Phil Hansbro
Scheme Equipment Grant
Role Lead
Funding Start 2007
Funding Finish 2007
GNo G0188192
Type Of Funding Other Public Sector - Commonwealth
Category 2OPC
UON Y

Miccroarrays to identify novel therapeutic targets for bird flu$14,500

Funding body: John Hunter Hospital Charitable Trust

Funding body John Hunter Hospital Charitable Trust
Project Team Conjoint Professor Peter Wark, Professor Phil Hansbro
Scheme Research Grant
Role Lead
Funding Start 2007
Funding Finish 2007
GNo G0187337
Type Of Funding Other Public Sector - State
Category 2OPS
UON Y

20064 grants / $793,907

PRC Priority Research Centre for Asthma & Respiratory Diseases$524,282

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Laureate Professor Paul Foster, Conjoint Professor Peter Gibson, Conjoint Professor Kenneth Beagley, Emeritus Professor Michael Hensley, Professor Phil Hansbro, Professor Joerg Mattes, Professor Alistair Sim, Conjoint Professor Peter Wark
Scheme Priority Research Centre
Role Investigator
Funding Start 2006
Funding Finish 2013
GNo G0186914
Type Of Funding Internal
Category INTE
UON Y

Surveillance and Analysis of Avian Influenza Viruses in Migratory Birds in Australia$249,625

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Professor Phil Hansbro, Dr Ian Barr, Conjoint Professor Peter Wark, Dr Paul Selleck, Dr Simone Warner, Laureate Professor Paul Foster, Dr Aeron Hurt, Dr Irene Peroulis, Dr John Curran, Conjoint Professor Peter Gibson
Scheme Potential Avian Influenza-Induced Pandemic
Role Investigator
Funding Start 2006
Funding Finish 2006
GNo G0186000
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

The interaction between airway epithelial cells infected with rhinovirus and lymphocytes from subjects with COPD$15,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Conjoint Professor Peter Wark
Scheme Project Grant
Role Lead
Funding Start 2006
Funding Finish 2006
GNo G0186106
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

Equipment - Microscope$5,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Conjoint Professor Peter Wark
Scheme PULSE Early Career Researcher of the Year Award
Role Lead
Funding Start 2006
Funding Finish 2006
GNo G0186168
Type Of Funding Not Known
Category UNKN
UON Y

20011 grants / $338,516

Mechanisms of bronchial epithelial cell activation in rhinovirus infection in asthma, COAD and normal airways$338,516

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Conjoint Professor Peter Wark
Scheme Training (Postdoctoral) Fellowships - Neil Hamilton Fairley Clinical Fellowship (Overseas)
Role Lead
Funding Start 2001
Funding Finish 2005
GNo G0180753
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

19981 grants / $45,500

The investigation of airway inflammation and cell death in acute severe asthma$45,500

Funding body: Asthma Foundation of New South Wales

Funding body Asthma Foundation of New South Wales
Project Team Conjoint Professor Peter Gibson, Conjoint Professor Peter Wark
Scheme Research Grant
Role Investigator
Funding Start 1998
Funding Finish 1999
GNo G0177660
Type Of Funding Donation - Aust Non Government
Category 3AFD
UON Y
Edit

Research Supervision

Number of supervisions

Completed8
Current12

Total current UON EFTSL

PhD2.45

Current Supervision

Commenced Level of Study Research Title / Program / Supervisor Type
2016 PhD Mechanisms and Therapeutic Targeting of Oxidative Stress in Lung Disease
PhD (Immunology & Microbiol), Faculty of Health and Medicine, The University of Newcastle
Co-Supervisor
2016 PhD Dietary Intervention to Reduce Exacerbations in Children with Asthma
PhD (Nutritional Biochemistry), Faculty of Health and Medicine, The University of Newcastle
Co-Supervisor
2015 PhD Impact of Azithromycin Therapy on Airways and Systematic Inflammation in Asthma Patients of Australia.
PhD (Medicine), Faculty of Health and Medicine, The University of Newcastle
Co-Supervisor
2015 PhD The Relationship Between Blood Eosinophilia, Exhaled Nitric Oxide and Airflow Obstruction in Asthma and COPD Patients from the Community of Busselton, Australia
PhD (Medicine), Faculty of Health and Medicine, The University of Newcastle
Co-Supervisor
2015 PhD Functional roles of unfolded protein response and mitochondrial dysfunction in innate immunity in airway epithelium.
PhD (Medicine), Faculty of Health and Medicine, The University of Newcastle
Principal Supervisor
2015 PhD Contribution of Cell Death to the Pathogenesis of Chronic Obstructive Pulmonary Disease (COPD)
PhD (Immunology & Microbiol), Faculty of Health and Medicine, The University of Newcastle
Co-Supervisor
2015 PhD Prescription of acute oxygen therapy in patients at risk of type 11 respiratory failure
PhD (Nursing), Faculty of Health and Medicine, The University of Newcastle
Co-Supervisor
2015 PhD Generational Effects of Smoking in Pregnancy
PhD (Immunology & Microbiol), Faculty of Health and Medicine, The University of Newcastle
Co-Supervisor
2014 PhD Chronic Obstructive Pulmonary Disease (COPD)
PhD (Immunology & Microbiol), Faculty of Health and Medicine, The University of Newcastle
Co-Supervisor
2013 PhD The Role of the PI3K Signalling Pathway in the Innate Antiviral Response of Airway Epithelial Cells
PhD (Medicine), Faculty of Health and Medicine, The University of Newcastle
Principal Supervisor
2013 PhD Investigation of the pathogenesis and potential therapeutic interventions of influenza in Asthma and COPD
PhD (Immunology & Microbiol), Faculty of Health and Medicine, The University of Newcastle
Co-Supervisor
2010 PhD Identification of Novel Therapeutics in Chronic Obstructive Pulmonary Disease/Emphysema
PhD (Immunology & Microbiol), Faculty of Health and Medicine, The University of Newcastle
Co-Supervisor

Past Supervision

Year Level of Study Research Title / Program / Supervisor Type
2015 PhD Characterising Innate Immune Responses and the Role of PD-1 in Patients with COPD
PhD (Medicine), Faculty of Health and Medicine, The University of Newcastle
Principal Supervisor
2015 PhD Mechanisms of Increased Susceptibility to Influenza Infection in Mouse Models of Chronic Lung Diseases
PhD (Immunology & Microbiol), Faculty of Health and Medicine, The University of Newcastle
Co-Supervisor
2015 PhD Oxidative Stress Impairs Mitochondrial Function in Healthy and Asthmatic Primary Bronchial Epithelial Cells
PhD (Medicine), Faculty of Health and Medicine, The University of Newcastle
Principal Supervisor
2014 PhD Role of Antioxidants in Rhinovirus-Infected Airway Epithelial Cells
PhD (Medical Biochemistry), Faculty of Health and Medicine, The University of Newcastle
Co-Supervisor
2013 PhD Investigation of the Immune Mechanisms in Pregnancy and Asthma Leading to Increased Susceptibility and Disease Severity to Respiratory Virus Infections
PhD (Medicine), Faculty of Health and Medicine, The University of Newcastle
Co-Supervisor
2013 Masters An Investigation of Body Composition in People With and Without Chronic Obstructive Pulmonary Disease (COPD)
M Philosophy (Medicine), Faculty of Health and Medicine, The University of Newcastle
Co-Supervisor
2011 PhD Immune Mechanisms that Promote the Development of Inducible Bronchus-Associated Lymphoid Tissue (IBALT)
PhD (Immunology & Microbiol), Faculty of Health and Medicine, The University of Newcastle
Co-Supervisor
2010 PhD Mechanism of Infection of Bronchial Epithelial Cells by Human and Avian Influenza Viruses
PhD (Medicine), Faculty of Health and Medicine, The University of Newcastle
Principal Supervisor
Edit

News

NHMRC

NHMRC funding success 2016

November 10, 2015

Conjoint Professor Peter Wark has been awarded more than $609,000 in NHMRC Project Grant funding commencing in 2016 for his research project How the placental protein Syncytin impairs maternal immune responses to influenza.

Conjoint Professor Peter Wark

New asthma therapy

August 26, 2014

A new therapy developed by Hunter Medical Research Institute (HMRI) and UK-based respiratory researchers has recorded a marked reduction in acute asthma exacerbations triggered by the common cold.

Conjoint Professor Peter Wark

Position

Conjoint Professor
Centre for Asthma and Respiratory Disease
School of Medicine and Public Health
Faculty of Health and Medicine

Focus area

Immunology and Microbiology

Contact Details

Email peter.wark@newcastle.edu.au
Phone (02) 40420110
Fax (02) 4985 5850

Office

Room 2107
Building Level 2, West HMRI building
Location Lot 1 Kookaburra Close New Lambton

,
Edit